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ABSTRACT 
 
 
Self-Learning, DVD-Based Education Versus Traditional Education Approaches to 
Improve the Safety of Warfarin Use among Patients with Atrial Fibrillation 
 
by 
 
 
Jessica Oliver Hatch, Master of Science 
 
Utah State University, 2015 
 
 
Major Professor: Dr. Heidi Wengreen 
Department: Nutrition, Dietetics, and Food Sciences 
 
 
Warfarin anticoagulation therapy is an essential component of atrial fibrillation 
(AF) management. There is a growing need to examine alternative education strategies to 
increase patient knowledge of warfarin independent of clinician time as there is limited 
time to instruct patients in most outpatient settings.  
A randomized education trial was conducted to determine if self-learning, DVD-
based education could increase patient knowledge regarding basic warfarin management 
and its interaction with herbal and dietary supplements (HDS).  
Study participants (n=120) with known AF on warfarin were randomized into 2 
groups: one-on-one education (n=60), and self-learning, DVD-based education (n=60). 
Participants completed a multiple-choice test 3 times over the course of the study to 
quantify knowledge increase and retention as a result of the intervention.  
Paired t-tests were used to show participants increased their knowledge from pre-
test to post-test (p=<0.001). Scores remained higher at the 3-month follow-up assessment 
	  iv 
compared to the pre-test assessment, indicating that participants retained information 
gained during the intervention (p=<0.001). ANOVA tests were used to examine 
differences in knowledge gained between education groups. The one-on-one education 
group scored higher on the post-test than did the DVD-based education group (p=0.026); 
however, there was no difference in scores by group at the pre-test or 3-month follow-up 
assessment (p=0.122, 0.187).  
The self-learning, DVD-based education increased patient knowledge of warfarin-
HDS interactions; the degree of retention of this information 3 months after the education 
was delivered was not different than that observed for those receiving the one-on-one 
education. This research provides evidence that self-learning, DVD-based education may 
be an effective way to educate AF patients regarding HDS management at a lower cost 
than one-on-one education delivered in a clinic or other healthcare settings.  
 (122 pages) 
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PUBLIC ABSTRACT 
 
 
Self-Learning, DVD-Based Education Versus Traditional Education Approaches to 
Improve the Safety of Warfarin Use among Patients with Atrial Fibrillation 
 
Jessica Oliver Hatch 
 
Atrial fibrillation (AF) is a common cardiac arrhythmia that requires extensive 
medical and pharmaceutical management. The coagulation antagonist warfarin is 
commonly prescribed to reduce AF-associated stroke. Although warfarin effectively 
mediates thromboembolitic risk, its management is complex as many factors influence its 
therapeutic range including: genetics, diet, medication, and herbal and dietary supplement 
(HDS) interactions.  Lack of patient knowledge regarding these factors contributes to 
poor patient outcomes.  With the emerging epidemic of AF, readily available educational 
tools are necessary to improve patient outcomes while reducing clinician burden.  
 The purpose of this study was to develop both a self-learning, DVD-based and 
one-on-one education program to educate patients with atrial fibrillation about the risks 
of HDS-warfarin interactions and to compare education method efficacy in AF disease 
management. This study found patients lack knowledge regarding HDS-warfarin 
management, and both DVD-based and one-on-one education models could increase 
patient knowledge regarding HDS-warfarin factors. It is hypothesized this education 
method may be employed to further educate chronic disease populations about essential 
disease-associated factors to improve outcomes while reducing clinical burdens.  
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
Abstract 
Atrial fibrillation (AF) is a common arrhythmia in clinical practice. Warfarin 
anticoagulation therapy is an essential component of AF management as it reduces stroke 
risk. However, warfarin has a narrow therapeutic index and, if uncontrolled, will pose 
significant risk of bleeding. Confounding factors must be identified to reduce stroke and 
bleeding risk. This document will explain the implications of an increasing AF 
population and the factors that influence warfarin management. Warfarin carries a risk of 
bleeding or thromboembolism but may be taken safely if influencing factors are 
accounted for.  
 
Introduction 
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. In 
patients with AF, thromboembolism is of concern as it can lead to stroke with significant 
morbidity and mortality. Warfarin anticoagulation has been shown to reduce stroke risk, 
particularly in patients with other factors that increase stroke prevalence, such as 
hypertension, diabetes, prior stroke, or heart failure.1-4 Therefore, good anticoagulation 
control becomes essential in patients with AF.5 
This document seeks to further define the AF diagnosis, to highlight the need for 
anticoagulant interventions to mediate AF-induced stroke risk, and to address the known 
interactions between warfarin and diet or other factors.  It also seeks to explain the 
implications of an increasing AF population and the importance of self-learning and/or 
group education to mediate warfarin-induced adverse events while reducing clinician 
	  
	  2 
burden. This paper identifies three key aims which, when completed, will help define the 
efficacy of alternative education modalities in elderly populations with AF.  If effective, 
this research will move to improve potential patient care in a disease, which has a high 
prevalence in the US population.  
 
Background 
 
DEFINITION OF ATRIAL FIBRILLATION 
Atrial fibrillation (AF) is cardiac arrhythmia caused by irregular electrical activity 
in the upper chambers of the heart. Abnormal electrical impulses interrupt atrial and 
ventricle systole which reduces the efficiency of heart contraction and diminishes overall 
cardiac output. 6-7 Although AF is often asymptomatic, the decrease in systemic blood 
flow causes blood stasis, particularly in lower cardiac chambers and appendages. As 
plasma pools in these areas, platelet aggregation risk is significantly increased.7-8 Blood 
cell aggregates, or thrombi, can travel through the circulatory system and become wedged 
in capillary structures in other organs, including the brain and lungs. Stroke or pulmonary 
embolism (PE) may result from these insults.9 Even a minor cardiac output reduction due 
to AF, as little as 10%, can place an individual at an increased risk for mortality because 
of altered coagulation patterns and subsequent predisposition for thrombus formation.8 
Seven percent of individuals with AF will experience thromboembolic events, which is a 
five-fold increase in stroke incidence when compared to the general US population.8-10  
Strokes resulting from AF are usually severe and are associated with a high rate of 
systemic organ damage and long-term disability when compared to strokes from alternate 
thromboembolic origins.11 As stroke and PE are associated with significant injuries and 
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mortalities, thromboembolism risk must be mediated to decrease AF comorbidities and 
their subsequent complications.7   
 
INCIDENCE, PREVALENCE, AND RISK FACTORS OF ATRIAL FIBRILLATION 
AF is the most common arrhythmia in clinical practice, and its incidence has 
increased in recent years.8 In 2010, the Center for Disease Control reported 1.2 million 
new AF diagnoses each year from 2000-2010.12 They further projected AF disease onset 
would double from 1.2 million cases annually to 2.66 million by 2030.12-13 To date, the 
incidence of this disease increases by as many as 2.3 million individuals every year, 
which far exceeds the previous disease predictions made by the CDC in 2010.10-11,14  
AF disease prevalence has also grown in past decades. In 2006, Heeringa et al 
reported one percent of the total US population had AF.15 In 2012, Colilla et al reported 
5.2 million, or 1.6% prevalence.13, 16 This trend is expected to continue. Projections show 
possible prevalence to increase to 12.1 million cases in 2030, a 7.6 fold increase from 
current population occurrence.13 Atrial fibrillation’s escalating diagnosis has been 
attributed to multiple factors including: coexisting cardiovascular diseases, rising obesity 
prevalence, improving healthcare, and increasing population age.8   
Although AF can be present without any underlying structural heart disease, most 
patients experience AF as a result of concurrent cardiac conditions and metabolic 
disorders including: hypertension, coronary artery disease, myocardial infarction, 
cardiomyopathy, and diabetes.9, 17 These conditions influence the normal systole of the 
cardiac chambers; therefore, AF is a common co-morbidity as these diseases progress. 
For example, hypertensive heart disease can increase AF disease development risk by 1.5 
fold.18 Although this is a relatively small increase in risk, hypertensive diseases occur 
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with great frequency in the general population; in 2011, the CDC reported 32.5 percent of 
U.S. adults had hypertension.12 As a result, 40-80% of AF cases are attributed 
hypertension.9, 19 
In addition, obesity is associated with an increase in AF prevalence.  Obesity 
increases one’s risk for concurrent health problems that can lead to AF, including 
cardiovascular diseases, elevated blood pressure, and diabetes. Therefore, AF incidence is 
expected to rise with the concurrent increase in obesity.17, 20  
Age is an independent risk factor of AF. Presently, 1 in 4 adults are at risk of 
acquiring AF as they age.17 AF prevalence is rare before the age of 50, but almost 10% of 
people greater than 80 years old are affected.14, 21 Medical advancements and current 
population demographics, including the large baby boomer population, are expected to 
dramatically increase the size of the elderly population in the United States.17   
 
TREATMENT OF ATRIAL FIBRILLATION 
AF is not an inherently malignant arrhythmia, but it can heighten concurrent 
cardiac conditions that result in stroke or PE, angina, vascular syndromes, and coronary 
artery disease.  Standard medical therapies such as electrical conduction or ablation 
procedures may correct or reduce atrial arrhythmia and establish appropriate cardiac 
patterns.22 These are effective treatment options, but they do not always completely 
alleviate atrial imbalance. Many patients are not able to receive these interventions due to 
other medical or physical limitations. Comprehensive medical care of AF must therefore 
include clinical interventions that address the arrhythmia while providing 
pharmacological anticoagulation therapies to reduce thromboembolic stroke risk.17, 22 
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The coagulation antagonist warfarin is commonly prescribed as a prophylaxis or 
treatment for thromboembolic complications associated with AF.23 This medication has 
been shown to reduce stroke by 75% when compared baseline populations without 
pharmacological interventions.8 The US Food and Drug Administration (FDA) estimate 
two million patients are placed on this anticoagulation therapy each year.24 Warfarin 
efficacy is particularly apparent in patients who have other conditions that may increase 
stroke risk such as hypertension, diabetes, prior stroke, or heart failure. 2, 4, 25-26  
 
WARFARIN MECHANISMS 
Warfarin reduces thrombus-related morbidity by interfering with vitamin K- 
dependent coagulation pathways and subsequently diminishing platelet aggregation. 
Reduced vitamin K, or hydroquinone, activates many clotting factors in both the intrinsic 
and extrinsic coagulation pathways that allow proper thrombus formation. Hydroquinone 
plays an essential role by post-translationally carboxylating glutamic acid residues on 
multiple clotting factor peptides. Blood coagulation could not take effect without vitamin 
K. 27 
As vitamin K exerts its effect on the clotting cycles, hydroquinone becomes 
oxidized. Also, uncoupled oxygen in plasma can oxidize vitamin K.  As a result of these 
two actions, vitamin K must be re-reduced to function. Quinone reductase and epoxide 
reductase enzymes can reduce oxidized vitamin K and re-establish hydroquinone 
functionality. These enzymatic processes significantly contribute to the body’s ability to 
maintain a constant supply of active vitamin K. Warfarin antagonizes the vitamin K 
reduction cycle by interfering with the quinone reductase and epoxide reductase enzymes, 
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thereby diminishing active clotting factors and significantly reducing the efficiency of the 
coagulation pathways.27  
Although the body heavily relies on the reduction of oxidized vitamin K to 
maintain an adequate supply of active vitamin K for coagulation, hydroquinone is also 
introduced into the body system from exogenous sources through the diet in green leafy 
vegetables and some legumes.  Endogenous vitamin K is synthesized by anaerobic flora 
found in the gastrointestinal tract. These sources of hydroquinone contribute to systemic 
vitamin K levels. Therefore, warfarin dosing must account for both the metabolism of 
vitamin K in the body and dietary intake to ensure coagulation is kept within a safe 
range.27 
 
WARFARIN MONITORING  
Warfarin therapies reduce stroke risk by as much as 64% through altered 
coagulopathy, but excessive therapy can increase bleeding risk, particularly in elderly 
populations.28-29 As a result, warfarin may remain significantly under-prescribed due to 
the possible risk of over-medicating that can cause hemorrhagic events.17  
Warfarin should be dosed to ensure appropriate coagulation without increasing 
hemorrhagic risk. However, maintenance doses of warfarin fluctuate significantly, 
ranging from less than two milligrams per day to more than ten milligrams per day.  
Medication variability stems from many factors including:  nutritional status, availability 
of both dietary and endogenous sources of vitamin k, genetic polymorphisms, hepatic 
function, medication clearance, intestinal absorption, schedule compliance, drug 
interactions, and herbal and dietary supplement intake.8, 30-32, Consistent blood coagulation 
monitoring is essential to account for these diverse sources of warfarin variability and to 
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prevent stroke or bleeding risk.8 Monitoring is especially important when one is initially 
placed on warfarin, as the previously mentioned patient-related factors are difficult to 
both identify and to determine their influence of warfarin dosing.7  
Coagulation adequacy is determined by assessing the International Normalized 
Ratio (INR). This test evaluates blood to determine how long it takes plasma to clot after 
a tissue factor is added. The INR evaluates the proportion of active and inactive vitamin 
K dependent factors in both the intrinsic and extrinsic clotting pathways.9 Normal INR 
ratios range from 0.8-1.2.  For most patients with AF, optimal INR ranges between 2-3. 
This value reflects a delayed blood clotting time to reduce stroke risk without increasing 
risk of hemorrhagic events. INR levels below two indicate uninhibited blood clot 
formation, which increases one’s risk for thrombus formation if the individual has poor 
blood circulation, as is the case with AF. An INR greater than three shows severe delay in 
clot creation and increased bleeding risk. 7-9 
The frequency one’s INR is in the therapeutic range (between 2-3) has been 
inversely correlated with major blood loss, thrombosis, and mortality.10 Many studies 
show that suboptimal anticoagulation control is commonplace; a meta-analysis of 67 
studies involving more than 50,000 patients on warfarin discovered that the INR was in 
the therapeutic range only 64% of the time.8, 33 This research suggests there is an urgent 
need to improve oral anticoagulation care for most patients.10  
 
WARFARIN AND HERBAL AND DIETARY SUPPLEMENTS 
Many herbal and dietary supplements (HDS) interact with warfarin.8 HDS 
therapies can augment warfarin through alterations in hepatic drug metabolism, 
competitive digestive and metabolic inhibition, warfarin displacement from albumin, and 
	  8 
direct gastrointestinal injury. HDS therapies can also influence the synthesis and 
degradation of clotting factors, thrombocytes, and the overall symbiotic relationship 
between the clotting cascades and warfarin functionality.8, 34-38 Many natural and herbal 
medications inhibit cytochrome p-450, which may escalate the warfarin response, thereby 
elevating the INR and significantly increasing hemorrhagic risk. Other products may 
decrease warfarin’s effectiveness by altering its metabolism or by influencing vitamin K 
synthesis or functionality, which can increase stroke risk.37  
Although HDS-warfarin interactions have been reviewed, it is difficult to identify 
interactions between herbal remedies and warfarin because HDS therapies have limited 
regulatory oversight and are known to have dramatic inconsistencies in HDS supplement 
content.34-37 As such, the absence of evidence regarding interactions does not negate 
potential HDS-induced warfarin alterations.38 Also, there are limited clinical trials to test 
interactions and direct literature is not extensive, making definitive recommendations 
difficult.5, 39   
There is a substantial individual dose-response relationship, making it difficult to 
give recommendations of HDS to individuals in a known safe range.38 It is hard to isolate 
specific HDS products and their interactions with warfarin in individuals who require 
multiple medications. Therefore, the implications of HDS therapies on long-term 
coagulation control remain unclear.35 
HDS-induced warfarin alterations are a widespread problem in clinical practice 
due to their extensive utilization by the US population.3, 8, 34,  37, 39 HDS consumption in the 
US increased by 380% from 1990-1997 and this trend is increasing. Potential interactions 
increase almost daily as new supplements enter the market.34 Many individuals who  
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consume HDS therapies are unaware of their potential interactions with warfarin. They 
believe these products are safe because they are natural. This belief exponentially 
increases potential risk as individuals do not always disclose their HDS use to healthcare 
professionals.38, 40   
Due to the high risk of interactions, HDS therapies may be used only with caution 
and under the direction of a healthcare professional.1 Patients may be able to take some 
HDS therapies with critical medical management. INR monitoring remains the best 
protection against major harm due to polypharmacy, and this value can be used to 
determine an individual’s response to HDS products.39 
Prior to initiating HDS therapies, patients must first consult with a health care 
professional. Medical teams must understand which HDS therapies are known to interact 
and what HDS products should be avoided while on warfarin (Table 1-1).  
Table 1-1. HDS Therapies Known to Interact with Warfarin 
Alfalfa Anise Arnica Bilberry Bladderwrack  
Bromelain Butchers 
Broom 
Cat’s Claw  
 
Celery  
 
Chamomile  
Choleys  Coenzyme Q10 Cordycephs Cranberry Dong quai 
Feverfew Fenugreek Fish oil Forskolin Garlic  
Ginger Gingko Balboa
  
Ginseng  Glucosamine Grape seed 
Green Tea Guggul Horse 
Chestnut 
Horseradish Inositol 
Hexaphosphate 
Licorice Multivitamins  Omega-3 acids Pau d’arco Prickly Ash 
Primrose Oil  Red Clover Reishi  SAMe  St John’s wort 
Sweet Clover  Sweet 
Woodruff 
Turmeric 
 
Vitamin E
  
Vitamin K 
White Willow Willow bark  Wheat Grass   
Bold Font shows products that should be avoided while on warfarin 
Normal font shows products that can be taken with warfarin but must be used with 
caution 
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If a product is approved, patients must take HDS products consistently to 
maintain appropriate INR values.  When interactions between HDS therapies and 
warfarin are suspected, INR monitoring should be increased.38 Patients must be instructed 
not to take any new medications, including herbal products, supplements, or over-the-
counter medications without the approval of their attending physicians. Dose responses 
must be closely monitored to reduce over or under-coagulation.34   
Conclusions 
Although warfarin effectively reduces thromboembolitic risk, its management is 
complex due to many influencing factors including: genetics, diet, medication, and HDS 
interactions.  Effective warfarin management relies on both attentive medical care teams 
and pro-active patients that understand key factors in anticoagulation.8 With the emerging 
epidemic of AF in an aging population, readily available and easy to use educational 
tools are necessary to improve patient outcomes by increasing patient knowledge and 
improving behavior while reducing clinician education burden.41 
 
Proposed Project Aims  
1. Develop a patient education program in DVD format that will increase patient 
knowledge concerning supplement drug interactions. The education will address: 
a. Why compliance to warfarin medication is critical 
b. The risks associated with supplement and herbal product use 
c. Commonly used supplements and herbal products that interact with 
warfarin 
d. How to read a supplement facts label 
e. Need to consult with a health care provider prior to: 
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i. Continuing any HDS therapy 
ii. Beginning any new HDS therapy 
iii. Making any changes to current HDS regimen 
2. Develop an equivalent education program for one-on-one format that include all 
components addressed in objective one act as a control group to assess the 
effectiveness of DVD-based education and its implications in reducing physician 
time required to educate patients when compared to one-on-one education.  
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CHAPTER 2 
 
ALTERNATIVE EDUCATION STRATEGIES IN AN AGING POPULATION 
 
Abstract  
 
Chronic disease prevalence is rising in an aging population. Common diseases, 
such as atrial fibrillation (AF), place clinical and economic burdens on healthcare 
systems due to increased medical management needs. Education deficits regarding 
subsequent medical therapies, such as warfarin, place patients at increased risk for 
adverse events. There is a growing need for alternative education strategies to increase 
patient knowledge and to minimize clinician burden. This document will evaluate the 
effectiveness of alternative education modalities to instruct a growing AF population. 
Self-learning education tools can be an effective instrument to educate patients and about 
long-term disease management.  
  
Introduction 
Chronic disease prevalence is rising in the aging US population.1-2 Common 
diseases such as atrial fibrillation (AF) require extensive medical management to 
optimize patient outcomes. The subsequent need for physician oversight and increased 
patient engagement places clinical and economic burdens on the already taxed healthcare 
system.2-4 For example, warfarin anticoagulation therapies are an essential component to 
reduce stroke risk in patients with AF.3-4 Although effective, warfarin requires close 
follow-up and monitoring because suboptimal medication control increases the 
probability of adverse hemorrhagic or thromboembolic events.1, 5  
In conjunction with medical supervision, adequate education regarding global 
warfarin management is essential to patient participation, safety, and symptom control. 
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Appropriate patient knowledge is associated with improved patient outcomes.6,7 
Unfortunately, patients often exhibit limited knowledge of their anticoagulation therapy 
and its cofactors, including herbal and dietary supplement (HDS) intake.8-10 Physician, 
pharmacist, and/or nurse led teaching in clinic and inpatient settings is predominantly 
underutilized because there is limited time to instruct patients about all essential warfarin-
related factors. These education constraints are expected to increase in proportion to the 
growing elderly population and chronic disease prevalence. 2,8,11-13 Therefore, alternative 
education strategies must be considered to increase patient understanding and warfarin 
regimen compliance independent of the one-on-one teaching models commonly used in 
clinical settings. 
This document will explore the implications of an aging population, patient 
knowledge deficits regarding warfarin management, the shortcomings of limited one-on-
one patient teaching opportunities, and how these factors relate to long-term regimen 
compliance and safety. It will also pose to examine appropriate education structuring for 
elderly adults with high chronic disease incidence. Finally, this text will consider 
alternative education strategies, including self-learning and group education teaching, to 
determine if these modalities can increase patient knowledge concerning basic warfarin 
therapies and HDS management while minimizing clinical burden.  
 
Background 
 
HEALTHCARE IMPLICATIONS OF A GROWING ELDERLY POPULATION  
US populations are living longer, healthier lives.14 In 1965, the average life 
expectancy was 70.2 years, and it will likely to advance to 80 years by 2020.15 Similarly, 
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the number of people over the age of 65 is growing rapidly due to the large baby boomer 
population. One of every 5 people will be over 65 by 2030.16 
Overall, elderly people are the largest consumers of American healthcare. A 
major goal of the healthcare system therefore must maintain health and prevent and/or 
delay chronic diseases in the US population.14,17 Consequently, there is a great need to 
develop methods to reduce healthcare costs and increase quality of care for the elderly.17  
 High prevalence diseases, such as AF, are expected to increase with the rising age 
of the overall population.1 As AF incidence increases, it poses a significant economic 
burden on the healthcare system. The medical burden associated with AF increased by 
18.8% from 1990 to 2010, and this trend is expected to continue.11 Also, warfarin 
anticoagulation-related episodes place significant clinician burden worldwide 
independent of AF medical management. The prevalence of warfarin use is expected to 
increase in proportion with advancing population age.4, 8  
These factors will increase the need for inpatient and outpatient medical 
treatments and therapies, pharmacological interventions, disease and medication 
monitoring to improve patient outcomes.4,8  However, treatments must also be cost-
effective to minimize the consequent healthcare and economic burdens presented by the 
large chronic disease population, as is the case with AF and warfarin therapies. 
 
ANTICOAGULATION CONTROL 
Warfarin continues to be a successful component of coagulation control despite 
bleeding risks due to its high efficacy in stroke prevention and clot degradation.18 
Although alternative anticoagulation therapies have been implemented in AF 
management, limited head-to-head trial comparisons have been completed to determine if 
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new medications are superior warfarin therapies.1 There are situations in which warfarin 
may continue to be an appropriate anticoagulant choice including: patients who are 
already comfortable with INR management, are not likely to comply with increased 
dosing requirements, are unable to take the new medications due to contraindications 
such as severe kidney disease or increase in pharmaceutical cost.1 
Even with alternative anticoagulation therapies, seven percent of elderly adults in 
the United States take warfarin.19 However, warfarin is frequently associated with adverse 
drug events.20 Its use requires routine international normalized ratio (INR) monitoring to 
maintain a tight therapeutic index. Inconsistent INR values place patients at increased 
risk of over- or under-coagulation that can lead to stroke, bleeding, and/or 
cardiomyopathy.2, 21  
Keeping the INR within prophylactic range is complex as many factors contribute 
to warfarin regulation. These factors include: genetic, hepatic, and digestive variation, 
vitamin K intake, and medication and/or HDS interactions.1 Warfarin control has 
improved over the past decades due to clinical trials and specialized anticoagulation 
clinics where close attention has been given to INR levels and its confounding factors.22 
However, poor warfarin related outcomes still occur. A patient’s INR may be out of 
range as much as 64% of the time an individual is on warfarin, and 93% of warfarin users 
may experience adverse events.23-24 Overall, there are as many as 4-7 serious bleeding 
events per 100 patient years of warfarin exposure, many of which cause morbidity and 
mortality.25  
Many elements complicate the clinical outcomes of warfarin therapy. Poor INR 
control and coagulation outcomes are most commonly associated with limited medical 
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oversight and inadequate patient understanding of warfarin and its influencing factors.8, 26-
27 Many sources suggest INR values are more often within the therapeutic range when 
patients have a greater knowledge of warfarin therapy, and poor patient knowledge was 
associated with worse coagulation control.6, 8-9, 28-29 For example, Kagansky et al. showed 
that patient INR values were more frequently within therapeutic range when patients 
received adequate education (45.1%) compared to those who were not adequately 
educated (34.9%).30 Also, insufficient education was associated with more bleeding 
events (5.2 events per 1000 patient months) when compared to an appropriately educated 
population (0.5 per 1000 patient months (p=<0.001)).30  
Patient warfarin literacy is a predictor of medication adherence.23, 28-31 Davis et al. 
reported patients do not follow medication-related recommendations as much as 50% of 
the time, and these participants could only state understanding of 37% of warfarin 
management components.28 In another study, Parker et al. reported that 21% of patients 
were non-adherent to warfarin recommendations; these patients more often missed pills 
rather than took too many.32 In both studies, patients often perceived they were more 
adherent to medical advice than they actually were. 28, 32 These research findings highlight 
the large gaps between clinical awareness of patient knowledge and their actual warfarin 
management comprehension and behaviors.6, 28, 32 The inability to follow appropriate 
regimens due to misunderstanding leads to acute exacerbations of chronic complications 
and reduces patient safety and outcomes. 6, 28, 32-34 Conversely, participants who have good 
information and understanding of medication guidelines are more likely to act as 
proactive participants in their healthcare decisions and will adhere to overall medical 
advice.35 
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Although some studies have not shown a significant association with adherence 
and good anticoagulation knowledge, other factors including vitamin K intake, 
medications, and genetics also influence coagulation levels. These components may 
confound study results.   Many factors contribute to warfarin efficacy and safety, and 
patient education should not be discounted, as patient understanding may be the most 
robust way to impact modifiable variability in INR management and improve coagulation 
control. 9, 28, 36-37 
 
WARFARIN ANTICOAGULATION KNOWLEDGE DEFICITS 
Evaluation of patient knowledge is the first step to improve quality of 
anticoagulation therapy education and patient care.38 Poor patient understanding may be 
easier to influence than medication metabolism, but knowledge deficits can be difficult to 
identify and correct.28 Overall, many patients have very low knowledge of AF symptoms, 
limited health literacy regarding warfarin medications, and are unable to identify signs of 
a thromboembolism. They also do not always comprehend the need for routine INR 
monitoring, consistent vitamin K dietary intake, caution with HDS therapies and drug-
drug interactions, and the need to disclose medication-related factors to health care 
professionals. 1, 6,  8-9, 34 
Successful anticoagulation treatments are dependent on patient warfarin 
knowledge. Hu et al. found 61% of their study population had insufficient warfarin 
understanding.39 Makaryus et al. discovered that less than 50% of individuals were able to 
list their diagnoses and outline the purpose of the medications they consumed.33 Similarly, 
another study found that while 75% of patients could state that factors like vitamin K 
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were significant to warfarin therapies, only 20% of individuals recognized there was a 
dose-dependent relationship between vitamin K and warfarin.6  
Overarching medical organizations have also recognized these knowledge deficits 
and the severe risks associated with poor warfarin comprehension. The Warfarin National 
Patient Safety Goal (NPSG) guidelines created by the Joint Commission identify key 
education factors that are essential to improve INR values and to reduce inadvertent 
complications from anticoagulant interventions.  These guidelines state education 
strategies should address the importance of medication monitoring, regimen compliance, 
and basic cautions regarding drug-food and drug-drug interactions (including HDS 
therapies).40-41  
Numerous studies have attempted to show patient education can increase INR 
control and improve patient safety, but study testing tools and questions have been 
inconsistent, making it difficult to corroborate findings across studies.42 Zeolla et al. 
examined previous studies’ methodologies and questions to create a validated self-
administered instrument to assess warfarin therapy comprehension.42 Their validated tool 
showed INR variability decreased if patients could state understanding of five education 
and testing domains including: basic drug information (such as dosing), adverse reactions 
associated with poor patient compliance, drug-drug and dietary interactions, and the need 
for long-term monitoring. 42 
Other researchers have supported the guidelines outlined by the Warfarin NPSG 
and Zeolla et al.6, 23, 29-30 Therefore, future study designs regarding warfarin education 
efficacy in long-term disease populations should address these key deficits.6, 32, 40-42  
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HERBAL AND DIETARY SUPPLEMENT KNOWLEDGE DEFICITS 
  According to the 2007 National Health Interview Survey, 39% of US adults take 
multivitamin and mineral supplements, and 17.7% of individuals consume herbal 
products or remedies.43-44 Many of these products can increase patient risk of under- or 
over-coagulation through altered warfarin metabolism or interfere with the coagulation 
pathway. Increased HDS use is associated with reduced INR control, which can intensify 
one’s risk for stroke or hemorrhage. 1, 10, 44-46 Chan et al. discovered 50% of their study 
population took more than one HDS therapy known to interact with warfarin. 
Additionally, individuals who took less than one HDS therapy fewer than four times per 
week were more likely to have an INR in range when compared to frequent users who 
took more than one HDS therapy more than four times per week (p=0.068).10   
Patients may still consume some HDS products while taking warfarin, but 
healthcare professionals must be aware of patient use to account for potential 
interactions.47-48 Patients must be transparent in supplement intake as simple changes 
HDS therapies can cause life-threatening complications.49-50 
Patients on anticoagulation therapy with warfarin should be educated about and 
monitored for possible drug-herb interactions.48 Research regarding patient HDS 
knowledge and warfarin are limited, but those select studies show patient awareness to 
warfarin and HDS interactions is poor. Over 50% of HDS users do not disclose their 
supplement intake to medical professionals.10 Individuals often do not know it is 
important to discuss their HDS use with care providers. 10, 36, 47 The vast majority of 
patients cannot identify products that potentially interact with warfarin.10, 47, 51 Further 
research would be helpful in identifying knowledge deficits and educating elderly 
patients regarding HDS-warfarin management.36 
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EDUCATING AN ELDERLY POPULATION 
 Although the need for chronic disease education is well established, the best teaching 
strategy for elderly patients with AF on warfarin has yet to be determined.33, 52 Disease 
and medication information can only increase patient knowledge and compliance if the 
education content and techniques are appropriate for the target population.1, 22, 53 
Therefore, educators must critically analyze patient demographics, education levels, and 
lack of previous knowledge to ensure education modalities are appropriate to effectively 
relay essential information to individuals for disease management.53-54  
Education programs for the elderly must be tailored to the functional and 
psychosocial conditions of the participants.37, 55 Historically, education programs 
structured on extensive quantitative data are difficult to understand. Even highly educated 
patients struggle with numerical data and its extrapolation to determine risk. Lengthily 
data and/or high amounts of medical jargon appear to have limited impact on patient 
knowledge retention and adherence. Education complexity minimizes the applicable 
components of education.53, 55 
Education for the elderly appears to be most effective when messages are 
provided as observational learning and/or health narrative techniques. 37 Information 
should be presented in a conversational format, and should also provide concrete 
messages that easily allow individuals to follow instructions.37, 53, 55 Written material 
should not exceed a seventh-grade reading level.42 These observational learning education 
principles have been proven essential in multiple disease formats, including AF and 
warfarin education for elderly populations.1, 55 Warfarin education materials are most 
effective when messages focus on essential patient safety topics rather than quantitative 
data regarding coagulation.56 Participants educated using these techniques are more likely 
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to recall essential factors that are important for appropriate coagulation control.37,53,55 See 
Table 2-1 for examples.  
 
Table 2-1. Examples of Inappropriate and Appropriate Education Techniques 
Inappropriate 
education 
technique 
Fish oil supplements are contraindicated in patients taking 
warfarin as these products decrease clotting factor VII levels and 
interfere with platelet aggregation (Buckley).   
Appropriate 
education 
technique 
You should not take fish oil supplements while you are on 
warfarin.  This product can raise your bleeding risk.  
 
 
CHALLENGES TO ONE-ON-ONE TEACHING  
In addition to appropriate content, education methods must be suitable for the 
expected practice setting.56 Major strides have been made to identify medical-related 
knowledge deficits in elderly populations, but effective education programs and policies 
have yet to be routinely implemented in many medical care areas.1, 14, 22, 52, 56  
Education is time consuming for clinicians, and patients are often overwhelmed 
by new diagnoses. Therefore, initial education usually addresses only critical elements of 
medication and disease management to prevent mortality.52-53, 56  
Even patients who receive formal education at the time of diagnosis do not always 
recall essential disease management factors. Patients who are new to warfarin therapies 
are at particular risk for poor knowledge retention.6 Winans et al. discovered patients 
educated by nursing staff on medical and surgical floors during admission for initial 
disease onset failed to gain sufficient knowledge to pass a follow-up warfarin therapy 
exam; their mean post-test score was only 55%.26 Metlay et al. showed patients who 
reported receiving initial warfarin education had lower hospitalization admissions due to 
inaccurate medication management over two years (p=<0.001). 23 However, researchers 
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discovered only 55% of participants reported they received medication instructions 
during admission. Those who reported lack of education had similar hospital admission 
risk as the general AF population.23 If patients do not recall receiving information about 
their medication, they are at an increased risk for adverse warfarin related events.26, 33, 38  
The high variability in patient recall regarding initial warfarin teaching may be 
explained by the high nursing-to-patient ratio when compared to one-on-one education in 
an outpatient clinic setting. There is also a large variability in education content and 
nursing explanations within a single medical facility.26 In general, hospital education by 
nurses can provide basic knowledge of warfarin management, but in-depth understanding 
of all essential education components is not found.39 
Knowledge retention from inpatient settings appears to be poor when compared to 
in-depth intervention group educations in coagulation clinics; however, universal changes 
to office scheduling patterns reduce time available in outpatient settings for education. 
Education tasks assigned to the general physician are growing.26, 57 Many individuals on 
warfarin have INR follow-up in pharmacy-run clinics, but these health care professionals 
also face severe time constraints. Practitioners are not always able to provide extensive 
education, and patients followed in these settings still show limited knowledge retention 
regarding global warfarin management.33 Baker et al. showed patients who received 
education about warfarin-food interactions in INR clinic settings frequently missed 
questions on follow-up exams.38  
In the current era of both physician and nursing shortages, continued one-on-one 
education and follow up is likely unfeasible for diseases that are highly prevalent in the 
community, such as AF.33 If patients do not receive follow-up education, knowledge 
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deficits will likely continue and can increase adverse event risk.39, 56 As a result, more 
complex elements of warfarin control, like HDS therapy management, are often 
neglected.33, 56-57 Much research highlights the need for continued education and long-term 
follow-up to ensure patients retain needed knowledge regarding therapies and are 
appropriately implementing medical recommendations.6, 26, 32, 39 
 
SELF-LEARNING EDUCATION PROGRAMS 
Patient-driven and self-learning education programs may reduce clinic burden in a 
time of shrinking financial and human resources.6 Videotape instruction has long been 
recognized as an effective education tool in the healthcare industry.61 If appropriately 
developed and implemented, these tools can provide similar education when compared to 
one-on-one teaching strategies.56, 58-59 Audiovisual presentations have been shown to be 
effective in chronic disease management if the presentations deliver essential education 
components and the audience-appropriate content is presented in a brief and focused 
manner.7, 12-13  
Self-learning strategies can standardize materials presented, which may reduce 
education content bias in populations.54, 57 Theoretically, consistent education content can 
decrease modifiable INR variability in warfarin management.6, 58, 60  
Wofford et al. reviewed many warfarin-related education studies using diverse 
teaching strategies such as one-on-one nurse or physician education and videotape 
sessions.56 Their meta-analysis found high variability in education content. However, 
when factors for content were accounted for, there was no difference shown in education 
gained across study groups.56 Ford et al also compared knowledge retention by comparing 
one-on-one education models to self-learning DVD education. These researchers 
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discovered patient post-test scores for the DVD group were unexpectedly higher, which 
may be attributed to increased patient engagement.60  
Self-learning education strategies are generally well received by patients.54, 58 
Programs that educate patients on appropriate self-management are linked to positive 
health-related outcomes including decreased complications and increased reported quality 
of life.6 Self-learning programs appear to increase patient-driven care and individual 
accountability for long-term disease management.56 
Follow-up education and content reiteration are important factors of long-term 
knowledge retention. Many studies have shown patients lack knowledge regarding 
appropriate warfarin monitoring even if initial education was provided.6 Video recordings 
may increase knowledge retention over time as participants may view these materials 
frequently.6, 56-57  
In conjunction with improved patient knowledge, self-learning programs can 
maximize office efficiency by delegating education to independent learning areas, like an 
office computer or DVD education in waiting rooms and homes.  If correctly made, these 
materials can provide low-cost, patient-centered education with minimal office 
operational impact.56-57  
Although effective, self-learning education has limitations. Primarily, patient-
driven learning limits patient-physician interaction. This reduces available patient time to 
ask follow-up questions regarding education implementation. Also, DVD-based programs 
require high patient engagement. Individuals must view required content to obtain any 
education benefits. 56-57 Many recent technologies, such as computers, tablets, and DVDs, 
are foreign to elderly populations. These individuals will likely continue to require in-
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person question time and to both navigate education materials and to clarify disease 
management needs.  Practitioners must be aware of these potential confounding factors 
when using these education strategies.6, 54  
 
Conclusions 
One-on-one education is difficult for high prevalence diseases, such as AF. As the 
elderly US population expands, clinicians will have less time to educate patients and 
patient knowledge may be compromised.53 Identifying knowledge deficits and improving 
patient understanding of warfarin use is critical to improve patient outcomes. When 
anticoagulation therapies are effectively monitored for accuracy and are accompanied by 
appropriate education, the majority of individuals can safely take warfarin.1, 59 Adherence 
requires commitment from both health care providers and patients to make sure the INR 
is in range and medication is taken in time.10, 36, 54 
Current research shows interactive, self-learning audiovisual tools, such as DVD-
based strategies, can educate patients about elements of chronic disease management 
while decreasing practitioner strains.53-54 Although standard and alterative teaching 
strategies have proven effective in educating and patients with AF regarding general 
warfarin management, little research has been done to address HDS knowledge deficits.36 
Further research is warranted to determine if these self-learning strategies can also be 
effective in educating an elderly AF population about HDS products.  
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CHAPTER 3 
 
SELF-LEARNING, DVD-BASED EDUCATION VERSUS TRADITIONAL 
EDUCATION APPROACHES TO IMPROVE THE SAFETY OF WARFARIN USE 
AMONG PATIENTS WITH ATRIAL FIBRILLATION1 
 
Abstract 
 
BACKGROUND: Warfarin anticoagulation therapy is an essential component of 
atrial fibrillation management. There is a growing need to examine alternative education 
strategies to increase patient knowledge of warfarin independent of clinician time, as 
there is limited time to instruct patients in most outpatient settings.  
OBJECTIVE: A randomized education trial was conducted to determine if self-
learning, DVD-based education could increase patient knowledge regarding basic 
warfarin management and its interaction with herbal and dietary supplements (HDS).  
METHODS: Study participants (n=120) with known AF on warfarin were 
randomized into 2 groups: one-on-one education (n=60), and self-learning, DVD-based 
education (n=60). Participants completed a multiple-choice test three times over the 
course of the study to quantify knowledge increase and retention as a result of the 
intervention.  
RESULTS: Paired t-tests were used to show participants increased their knowledge 
from pre-test to post-test (p=<0.001). Scores remained higher at the three-month follow-
up assessment compared to the pre-test assessment, indicating that participants retained 
information gained during the intervention (p=<0.001). ANOVA tests were used to 
examine differences in knowledge gained between education groups. The one-on-one 
1Jessica Hatch, Heidi Wengreen, Barbara Fiechtl 
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education group scored higher on the post-test than did the DVD-based education group 
(p=0.026); however, there was no difference in scores by group at the pre-test or 3-month 
follow-up assessment (p=0.122, 0.187).  
CONCLUSIONS: The self-learning, DVD-based education increased patient 
knowledge of warfarin-HDS interactions; the degree of retention of this information three 
months after the education was delivered was not different than that observed for those 
receiving the one-on-one education. This research provides evidence that self-learning, 
DVD-based education may be an effective way to educate AF patients regarding HDS 
management at a lower cost than one-on-one education delivered in a clinic or other 
healthcare settings.  
 
Introduction 
 
ATRIAL FIBRILLATION AND WARFARIN MANAGEMENT  
Chronic disease prevalence is rising in the aging US population.1-2 Atrial 
fibrillation (AF), a common chronic disease, requires extensive medical management to 
optimize patient outcomes.3-6 The subsequent need for medical interventions, physician 
monitoring, and increased patient engagement places clinical and economic burdens on 
the already taxed healthcare system.7-9  
In patients with AF, thromboembolism is of concern as it can lead to stroke with 
significant morbidity and mortality.1-5 Warfarin anticoagulation has been shown to reduce 
stroke risk, particularly in patients with other factors that increase stroke prevalence, such 
as hypertension, diabetes, prior stroke, or heart failure; therefore, good anticoagulation 
control becomes essential in patients with AF. 7, 10-13 Warfarin, though effective, requires 
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close follow-up and monitoring as suboptimal medication control increases the 
probability of adverse hemorrhagic or thromboembolitic events. 6-9, 14  
 
EDUCATION NEEDS IN THE AF POPULATION 
In conjunction with medical supervision, adequate education regarding 
comprehensive warfarin management is essential to patient participation, safety, and 
symptom control. Appropriate patient knowledge is associated with improved outcomes; 
unfortunately, patients often exhibit limited knowledge of their anticoagulation therapy 
and its cofactors, including herbal and dietary supplement (HDS) intake.4, 15-18 It is 
imperative that teaching regarding HDS management be included with standard warfarin 
education to avoid potentially lethal interactions and high variability within standardized 
International Normalized Ratio (INR) values.4 
Research regarding patient HDS knowledge and warfarin are limited, but select 
studies show patients’ awareness of interactions between warfarin and HDS therapies is 
poor. 4,18-19 Over 50% of HDS users do not disclose their supplement intake to medical 
professionals.4,18-19 The vast majority of patients cannot identify products that potentially 
interact with warfarin.18-20 
  
EDUCATION CONSTRAINTS IN CLINICAL SETTINGS 
Although education is essential for patient safety, there is limited time to instruct 
patients about all warfarin-related factors in clinical or inpatient settings. General clinic 
flow does not allow for comprehensive education due to time constraints. Healthcare 
professionals must address multiple disease and medication factors during a typical 
outpatient appointment. As a result, there is limited time to both identify and to correct 
patient knowledge deficits in clinical settings. During a typical visit to a healthcare 
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professional, a patient will only receive short (three to five-minute) education at the end 
of an appointment and may therefore only receive fragmented education over many 
outpatient visits. 4-5, 9, 19-20 
The limited time for patient education coupled with poor patient retention will 
increase in proportion to the growing elderly population and chronic disease prevalence; 
therefore, alternative education strategies must be considered to increase patient 
understanding and warfarin regimen compliance independent of standard teaching 
models commonly used in clinical settings. 4-5, 9, 19-20 
 
ALTERNATIVE EDUCATION STRATEGIES 
Patient-driven and self-learning education programs may reduce clinical burden in 
a time of shrinking financial and human resources.21 Video instruction has long been 
recognized as an effective education tool in the heath care industry.22 If appropriately 
developed and implemented, DVD-based teaching methods may provide similar 
educational efficacy when compared to one-on-one teaching strategies, and these 
approaches are associated with better patient retention.23-25 Concise and focused 
presentations can effectively educate populations about chronic disease management if 
they outline essential educational components. 17, 26-27 
DVD-based educational tools are most efficacious in elderly populations if 
messages are presented in a conversational format and provide instructions that are easy 
to follow.2,2 8-29   Patient instruction should give definitive recommendations while 
providing minimal quantitative or numerical data. Written materials and testing tools 
should not exceed a seventh-grade reading level.28 Participants educated using these 
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techniques are more likely to recall essential factors that are important for appropriate 
coagulation control. 2, 28-29    
Education content must address comprehensive disease management to improve 
patient outcomes.30 Many studies have attempted to address the gap between warfarin 
education and patient behaviors, but inconsistent teaching and evaluation methods make 
it difficult to corroborate findings across studies.30 Zeolla et al. reviewed previous studies’ 
methodologies and developed examination questions to create a validated testing measure 
to determine what patients needed to know to have minimal INR variability.30 This 
validated tool calls for five education and testing domains including: 1) basic drug 
information an medication management, 2) adverse reactions associated with poor patient 
compliance, 3) drug-drug interactions,  4) dietary interactions, and 5) the need for long-
term medication monitoring. 30 
Similarly, the Warfarin National Patient Safety Goal (NPSG) Guidelines created 
by the Joint Commission identified key education factors that are essential to improve 
INR values and to reduce inadvertent complications from anticoagulant interventions.  
These guidelines address the importance of medication monitoring and regimen 
compliance as well as basic cautions regarding drug-food and drug-drug interactions 
(including HDS therapies).31-32 Future study designs regarding warfarin education in long-
term disease populations should address the education domains addressed by Zeolla et al. 
and the NSPG guidelines.21, 30-33    
The study described here is a prospective, randomized education trial designed to 
compare the efficacy of self-learning, DVD-based education strategies to one-on-one 
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teaching methods to increase patient knowledge concerning basic warfarin therapies and 
HDS management.  
 
Methods 
 
SUBJECT RECRUITMENT AND RANDOMIZATION  
A randomized education trial was developed in cooperation with Utah State 
University, Logan, Utah, and Intermountain Healthcare, Salt Lake City, Utah. 
Institutional Review Board (IRB) approval was obtained through both collaborators’ 
organizations prior to beginning participant enrollment.  Study participants were recruited 
from the Intermountain Rhythm Specialist Clinic at Intermountain Medical Center, 
Murray Utah, from October 8, 2010 to February 9, 2011. Individuals with known AF who 
were receiving warfarin anticoagulation treatment (excluding those who had their INR 
time based upon genotyping for variance in vitamin K metabolism) were invited to 
participate. Individuals provided signed informed consent prior to participating in the 
study interventions. 
Subjects (n=120) were randomized into two education groups: one-on-one 
(n=60), and self-learning, DVD-based education (n=60). Group randomization was 
created using an Excel software-generated randomization chart to determine which 
individuals were placed in each group.  All patient recruitment, education, and follow-up 
practices were performed in compliance with IRB guidelines.  
 
INSTRUMENT DEVELOPMENT 
The education programs were made to assist and to supplement education 
provided in a typical outpatient appointment. The educations taught HDS-warfarin 
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management skills in one sitting, rather than the fragmented education that may or may 
not be provided over many medical visits.  
Both education programs addressed basic warfarin management principles as 
outlined by Zeolla et al. and NSPG guidelines including: regimen compliance and 
adverse reactions associated with poor control. The education was also designed to 
increase patient awareness of HDS-warfarin interactions. Design structure, reading level, 
and content reflected previous study designs that showed statistically significant 
reduction in warfarin INR variability after education was completed.21,30-36 The education 
domains included: why compliance to warfarin medication is critical, the risks associated 
with supplement and herbal product use, commonly used HDS products that interact with 
warfarin, and how to read a supplement facts label. Education reiterated the need to 
consult with a healthcare provider prior to beginning any new HDS therapy or making 
changes to a current HDS regimen.  
The one-on-one education was created as a structured curriculum that outlined 
specific education objectives, required discussion points, and suggested phrasing to 
reduce education variability. Participants in the one-on-one education group also received 
handouts outlining education objectives to view at home. All one-on-one teaching was 
completed by three trained and CITI certified instructors. The DVD-based education 
addressed identical objectives as outlined in the one-on-one education. Both the 
education programs took twenty minutes to complete. 
The pre-test, post-test, and three-month follow-up tests included the same nine, 
multiple-choice questions which were based on the Zeolla et al and NSPG guidelines 
(Appendix A).  The exams intended to assess participant knowledge of the education 
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domains and objectives addressed in education both groups. A panel of education and 
anticoagulation specialists who had patient care experience with warfarin management 
verified education content and face validity. Content reviewers included two pharmacists, 
three registered dietitians, and a cardiologist. 
 
DESIGN IMPLEMENTATION 
 
The pre-test was given before either education intervention was administered to 
assess patient’s existing knowledge of basic warfarin safety and HDS-warfarin 
interactions (one-on-one n=60, DVD n=60). Group one received the one-on-one 
education with an in-person instructor directly following the pre-test administration. 
Group two received the self-learning, DVD-based education to watch in their own home. 
Due to technology and space constraints in the clinic, participants did not view the DVDs 
at the clinic.  
Participants from both groups completed an initial post-test after education was 
received. Group one completed the post-test directly after the education. Participants who 
received the DVD-based education were contacted via telephone one week after they 
received the DVD, and this group was called five times over seven days after the initial 
phone call was made to attempt post-test completion. Participants who did not complete 
the post-test after these calls were made were considered dropouts and were not contacted 
for further information. Twenty-one percent of all study participants completed the pre-
test but did not complete the post-test (one-on-one n=60, DVD n=35). In addition to the 
questions asked at the pre-test, all participants who completed the initial post-test were 
asked to identify if they would make any changes as a result of the education. 
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The 3-month follow-up exam was administered to both groups via telephone three 
months after the post-test was completed to quantify knowledge retention of HDS-
warfarin interactions over time (one-on-one n=39, DVD n=21). All participants were 
contacted five times over seven days if the follow-up test was not completed on a 
previous telephone call. Fifty percent of participants did not complete the 3-month 
follow-up assessments. Participants who finished the 3-month post-test also completed a 
satisfaction questionnaire to assess patient-perceived efficacy of the provided education. 
No adverse events or unintended effects were identified over the course of the study. 
 
STATISTICAL ANALYSIS  
 
Analyses were completed using SPSS statistical software. Criteria for statistical 
significance included a 95% confidence interval, and the p-value of the two-tailed 
significance was set at <0.05.  
Chi-square analysis was used to determine if there were any differences in 
demographic variables including age and gender by group assignment. Fischer’s exact 
analysis was used if the data comparison frequency was less than five (i.e. gender and 
HDS intake). Two-tailed, paired t-tests were used to examine differences in pre-test 
(range 0-8), post-test (range 3-9), and three-month follow-up exam scores (range 3-9) and 
the self-reported number of behaviors the participant intended to change for the overall 
population and each study group, independent of the other group. A repeated measures 
analysis of variance (ANOVA) was used to examine whether change in mean scores 
differed by group over time.  In these analyses, the knowledge scores were coded as a 
three level factor (pre-test, post-test, and 3-month follow-up), and results were used to 
examine the effect of group on knowledge scores over the three assessment periods. An 
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interaction term for the three level factor and group was noted as significant (p=<0.001). 
Multivariable ANOVA tests included gender and age as covariates.  
As this study experienced a high level of dropout, demographic and mean post-
test scores of the dropout population were compared to those who completed the 3-month 
follow-up test via an ANOVA and chi-squared analyses.  
 
PRIMARY AND SECONDARY OUTCOME MEASURES 
Primary research outcomes aimed to determine if education would improve 
patient knowledge regarding HDS-warfarin management. Secondary research outcomes 
posed to determine if there was a difference in knowledge gained between education 
methods in clinical settings.  
 
Results 
 
DEMOGRAPHIC ANALYSIS  
 
Analysis of demographic data revealed study groups were not significantly 
different in terms of age, education, or HDS intake (p=0.96, 0.85, 0.69 respectively; 
Table 1). Of note, there were more males in the DVD-based group when compared to the 
one-on-one group, and this difference reached statistical significance (p= 0.03; Table 3-
1).   
Seventy-two percent of the study population consumed vitamin or mineral 
supplements, and 45% of individuals consumed herbal products. Of those individuals 
who reported HDS use, 85% reported routine HDS intake (once daily). Individuals 
frequently reported they used products that are known to interact with warfarin. Of 
concern, 54% of study participants reported they did not talk to medical professionals 
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regarding their HDS intake, and 46% of these individuals did not feel there was a need to 
address HDS intake with their healthcare provider. These results reflect previous studies’ 
findings that HDS product use is widespread in populations with AF, and consumers have 
limited understanding their implications in warfarin management. 4,18-19 
 
 
  
 
 
 
 
Table 3-1. Participant Characteristics by Education Group (n=120) 
 DVD One-on-one p-value (2-tailed) 
Male, n (%) 41 (70) 25 (42) 0.031*  
Age, mean (SD) 70.4 (10.5) 72.3 (11.9) 0.961 
Education Level, n (%)  0.852 
Some High School, 
n (%)  
2  (3.4) 3 (5.1)  
High School 
Graduate, n (%) 
30 (51.7) 28 (48.3)  
College Graduate, 
n (%) 
28 (48.3) 25 (43.1)  
Take 
Supplements4, n 
(%) 
40 (69) 43 (72.9) 0.691 
Take Herbal 
Products5, n (%)  
29 (50) 24 (40.7) 0.361 
Pre-test Mean 
Score, mean (SD)  
3.7 (1.6) 6 4.3 (1.6) 7 0.1223 
1 Fisher’s Exact Test, 2 Chi-Square Analysis, 3 ANOVA Analysis 
4 Supplement use is defined as ingestion of a pill, capsule, tablet, or liquid containing 
a vitamin or mineral that is intended as a supplement to the normal diet.  
5 Herbal product use was defined as intake of a pill, capsule, tablet, or liquid 
containing an herb or other plat product that is intended to supplement the normal 
diet.  
6 n=59, 7 n=60 
* p-value for significance = < 0.05 
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Paired sample t-tests were used to examine differences in scores from the pre-test to 
the post-test, post-test to 3-month follow-up, and pre-test to 3-month follow-up. 
Participants increased knowledge from pre-test to post-test (p= <0.001; Table 3-2). 
Researchers observed no statistically significant difference at the 3-month follow-up 
assessment compared to the post-test (p=0.051; Table 3-2), indicating no difference in 
mean scores between groups. Scores remained higher at the three-month follow-up 
assessment compared to the pre-test assessment, indicating that participants retained 
information gained during the intervention (p=<0.001; Table 3-2). 
Both groups showed statistically significant improvement in knowledge from pre-test 
to post-test, indicating both groups gained knowledge from the education (p=<0.001 for 
both groups; Table 3-2). The one-on-one group had statistically significant higher scores 
at the post-test when compared to the DVD-based group (p=0.03), but the variance in 
Table 3-2.  Mean scores from pre-test to post-test; post-test to 3-month follow-up test; 
pre-test to 3-month follow-up test; test an assessment of knowledge for overall education 
population and within groups 
 Pre-test Score, 
mean (SD)  
Post-test Score, mean 
(SD) 
p-value (2-tailed)* 
All, n= 97 4.13 (1.7) 6.8 (1.5) <0.001* 
DVD, n=37 3.7 (1.6) 6.6 (1.4) <0.001* 
One-on-one, n=60 4.3 (1.6) 7 (1.1) <0.001* 
 
 Post-test Score, 
mean (SD) 
Follow-up Test Score, 
mean (SD) 
p-value (2-tailed)* 
All, n=60 6.8 (1.5) 6.6 (1.3) 0.051 
DVD, n= 21 6.6 (1.4) 6.9 (1.3) 0.20 
One-on-one, n=39 7 (1.1) 6.4 (1.3) 0.005* 
 
 Pre-test Score, 
mean (SD) 
Follow-up Test Score, 
mean (SD) 
p-value (2-tailed)* 
All, n=60 4.13 (1.7) 6.6 (1.3) <0.001* 
DVD, n=21 3.7 (1.6) 6.9 (1.3) <0.001* 
One-on-one, n= 39 4.3 (1.6) 6.4 (1.3) <0.001* 
* p-value for significance = < 0.05; paired t-tests 
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mean scores between groups was only 0.3 points, which has little clinical relevance to 
differences in knowledge gained. Also, the one-on-one group completed the post-test 
directly following the education. The DVD-based group was contacted at least one week 
after receiving the DVD to complete the post-test; therefore, time could be a factor in 
difference regarding post-test scores. 
The DVD-based group had higher mean scores from the post-test to 3-month follow-
up within the group, but the difference between groups was not statistically significant 
(p=0.20; Table 3-2), indicating no significant change in knowledge retention from the 
post-test to the 3-month follow-up test. Interestingly, the one-on-one group showed a 
statistically significant reduction in knowledge retained from post-test to 3–month follow 
up (p=0.005; Table 3-2). A reduction in knowledge retained from post-test to 3-month 
follow-up test was not observed for the DVD-based education group (p=0.20; Table 3-2).  
Overall, both the DVD-based and one-on-one groups had a statistically significant 
increase in knowledge from pre-test to 3-month follow up scores (p=<0.001; Table 3-2). 
There is no statically significant difference in 3-month follow-up scores between groups 
(p=0.187).  
A repeated measures analysis of variance (ANOVA) was used to examine whether 
the change in scores was different by group over time. The interaction term of group over 
time was included in the model and found to be significant (p=<0.049). This indicated 
there was a differential effect of change in knowledge scores over time by group. 
Participants in the DVD-based group had higher scores at the 3-month follow-up than 
they did at the post-test, whereas participants in the one-on-one group had lower scores at 
the 3-month follow-up than they did at the post test. This finding suggests that the DVD-
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based group may have retained and internalized information to a greater degree than 
those in the one-on-one group. This interaction is visually displayed in Figure 3-1.  
 
Figure 3-1. ANOVA line graph analysis by group over time 
 
 
 
However, gender was associated with both group assignment and knowledge 
score at the 3-month follow-up exam (p=0.025). A repeated measures ANOVA was 
conducted while controlling for gender, age, and education level to determine if the 
variability in these factors would account for differences in scores between groups.    
After controlling for gender, age, and education in the multivariate repeated 
measures ANOVA, the interaction term representing the differential effect of group on 
scores over time (group*time) was attenuated and was no longer significant (p=0.07). 
This finding suggests that the differences in knowledge retention over time are associated 
with these factors, and the differences across groups may account for the statistically 
significant difference between groups.  
Score	   	  
p=	  0.049	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Even when accounting for covariates that may influence group scores over time, 
overall findings suggest both education modalities increase patient knowledge regarding 
HDS-warfarin management, and both are associated with good retention over time.  
PATIENT-STATED CHANGE AND SATISFACTION 
 Patients were asked to identify changes they would make as a result of the 
education at the time of the post-test. Overall, the participants reported they would make 
an average of 2.59 out of 6 possible changes as a result of the education, and there was no 
significant difference in number of possible changes between education groups (p=0.48; 
Table 3-3). Possible changes are listed in Table 3-4. 
Of the reported behavior changes, 63% of participants stated they would consult 
with a medical professional regarding their current HDS intake, and 67.5% stated they 
would talk to their medical team regarding prospective use. Sixty-nine percent of 
participants also stated they would read a supplement facts label on current or prospective 
products to verify content. There were no differences in reported behavior change 
components between groups (Table 3-4).   
These stated behavior changes are encouraging as patients are not likely to recall 
all products that interact with warfarin, but transparency of intake to their healthcare 
provider will likely allow better management, INR control, and patient safety on 
warfarin.   
 
Table 3-3. Mean Behavior Changes Across Groups, n=97, Range 0-6 
 DVD, n=37 One-on-one, n=60 P-value (2-tailed) 
Overall reported 
change, Mean (SD) 
2.68 (1.17) 2.5 (1.29) 0.48 
*Significance = <0.05, ANOVA Analysis 
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Participants completed a satisfaction questionnaire upon finishing the 3-month 
follow-up exam to inspect patient-perceived efficacy of the education. Both groups 
reported the frequency they viewed the education materials about two times after 
completing the post-test, and this was not statistically significant between groups (p=0.8; 
Table 3-5).  
Participants were asked to rank their satisfaction for the overall education. 
Components of satisfaction included the usefulness of content and provided materials and 
if the participant felt more comfortable with both warfarin and HDS intake as a result of 
the education. Satisfaction rating was ranked from zero to four; zero being not satisfied, 
and four being completely satisfied. Participants reported average satisfaction of 3.5 out 
of 4, indicating participants were highly satisfied with education provided, and there was 
no statistical difference found regarding any satisfaction rating component between 
groups (p=0.4; Table 3-5).  
Table 3-4. Reported Behavior Changes, n= 97 
Reported Behavior Change 
Component 
DVD, 
n=37 
One-on-one,  
n=60 
p-value (2-
tailed)* 
Continue current HDS regimen,  
n (%) 
10 (28.6) 24 (40) 0.28 
Stop consuming HDS products,  
n (%) 
3 (5) 4 (11.4) 0.42 
Talk to medical professional 
regarding current HDS use, n (%) 
35 (58.3) 24 (68.6) 0.36 
Talk to medical professional 
regarding prospective HDS use, n 
(%) 
45 (75) 21 (60) 0.17 
Continue to refrain from consuming 
HDS products, n (%) 
20 (33.3) 5 (17.1) 0.10 
Read label on HDS products one 
may or is currently taking, n (%) 
43  (71.1) 24 (68.6) 0.82 
* p-value for significance = < 0.05; Chi-Square Analysis 
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Table 3-5. Mean Patient Reported Satisfaction Across Groups, n=60, Range 0-4 
Reported Satisfaction 
Component 
DVD, n=21 One-on-one, 
n=39 
p-value (2-
tailed)* 
Frequency viewed provided 
materials, mean (SD) 
1.9 (0.7) 2 (0.76) 0.8 
Overall satisfaction rating, 
mean (SD) 
3.5 (0.5) 3.4 (0.5) 0.4 
Useful content, mean (SD) 3.5 (0.5) 3.4 (0.5) 0.5 
More comfortable with 
warfarin prescription, mean 
(SD) 
3.2 (0.7) 3.2 (0.6) 0.98 
More comfortable with HDS 
management, mean (SD) 
3.3 (0.6) 3.3 (0.5) 0.98 
*Significance = <0.05, ANOVA Analysis 
 
 
 
ANALYSIS OF PARTICIPANTS WHO DROPPED OUT OF THE EDUCATION 
 
 A significant study limitation included high rates of dropout. Of the 120 initial 
participants, only 50% of participants completed the final 3-month follow-up exam.  This 
was possibly due to high patient-engagement required to complete all follow-up 
examinations, or technology knowledge limitations in an elderly population. ANOVA 
was used to examine differences between post-test data of individuals who dropped out 
of the education and those who completed the 3-month follow-up exam.  
There were no differences in post-test score age or education level between study 
dropouts and those that completed the education (p=0.07, 0.958, 0.3; Table 3-6).   Of 
note, there is a gender effect here as well; more males dropped out of the education than 
those that completed the education (p=0.007; Table 3-6).  
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Table 3-6. Participant characteristics by individuals who dropped-out versus those who 
completed the follow-up examinations (n=116) 
 Dropped Out 
After the Post-
Test 
Completed 3-month 
follow-up exam 
p-value (2-tailed) 
Male, n (%) 40 (60.6) 26 (30.4) 0.0071 
Age, n (SD) 71.2 (10.4) 71.3 (12.1) 0.9582 
Education   0.3122 
Some High School, n 
(%) 
3 (5.2) 2 (3.4)  
High School Graduate, 
n (%) 
 27 (47) 31(53)  
College Degree, n (%) 28 (47.8) 25 (45.6)  
Take Supplements, n 
(%) 
34 (41) 49 (59) 0.0041 
Take Herbal Products, n 
(%) 
25 (47) 28 (53) 0.7111 
Pre-test Score, mean 
(SD) 
4.1 (1.8) 4.1 (1.6) 0.8763 
Post-test Score, mean 
(SD) 
6.3 (1.9) 6.0 (1.2) 0.0723 
1 Fisher’s Exact Test, 2 Chi Squared, 3 ANOVA Analyses  
 
  
STUDY FINDINGS 
 
 This study showed patients had a lack of knowledge regarding HDS therapies and 
warfarin management. Our research findings mirror previous studies’ results in regards to 
patient knowledge of HDS therapies. 4, 18-19, 30 Poor patient understanding of HDS-warfarin 
management places patients at increased risk for adverse reactions.18-19 
Analysis revealed there is a gender difference that may have influenced study 
results; it appears that men gained more knowledge over time when compared to females, 
but males more frequently dropped out of the education.  
Overall, when gender differences were accounted for, results of the study suggest 
that both self-learning, DVD-based education and one-on-one teaching strategies can 
successfully increase AF patient knowledge regarding HDS-warfarin management. This 
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study shows both education programs can effectively increase patient knowledge, and 
education modalities are also well received by participants, which increases their viability 
in high patient load areas. 
 These findings indicate alternative education strategies may be employed in high-
prevalence populations to increase patient knowledge while minimizing clinical and 
physician burden. Although one-on-one education programs are considered an education 
gold standard, this method may not be effectively implemented in clinical settings, as it 
requires additional patient and clinician time; well-educated staff must be available to 
provide the education. As a result, self-learning, DVD-based education methods may 
educate patients about more intensive components of warfarin management, such as HDS 
therapies, without adding significant clinician training or time.  
 
Limitations 
 In a time of joint-accountability in healthcare, high patient engagement is required 
to ensure patient safety and appropriate medical management. High patient engagement is 
associated with increased education levels, and participant knowledge.5-7 Unfortunately, it 
was difficult to obtain follow-up data for much of our study population. This is 
concerning as participants who did not follow-up may not receive benefits of the 
education.  Results of statistical analysis did not reveal any large differences across 
groups save for gender, yielding little explanation as to the factors that contribute to high 
patient dropout.  
Also, self-learning, DVD-based educations provide limited time to ask follow-up 
questions. If DVD education strategies are to be effective, patients must know to follow-
up with healthcare providers to ensure clarifications.  
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Conclusions 
Future study design and implementation should identify key factors to facilitate 
further patient participation or accountability for education. This could include 
employing technology-facilitated education in the patient waiting room in the form of a 
video for participants to view, or implementing a web-based technology.  
Here we assessed observed gains in knowledge over baseline at both the post-test 
and 3-month follow-up period for both groups. However, this study did not examine 
actual warfarin variability in the form of INR testing. Many research studies have shown 
adequate education about warfarin management can reduce patient INR variability. 29-36 
As such, further research is warranted to examine if DVD-based education regarding 
HDS management yielded actual changes in patient behavior and improved INR values.  
While further testing is needed to discover methods of education implementation 
in clinical settings, this pilot study showed self-learning, DVD-based education can 
increase patient knowledge regarding HDS-warfarin management, and is associated with 
patient reported behavior changes. These education methods may be further examined to 
increase patient knowledge regarding essential disease-related components in clinical 
settings. 
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CHAPTER 4 
SUMMARY AND CONCLUSIONS 
 
 
Abstract 
Warfarin anticoagulation therapies continue to be a key treatment component for 
many individus with atrial fibrillation (AF). Despite its high efficacy, warfarin use 
requires extensive patient knowledge about many factors that may interact with warfarin, 
such as herbal and dietary supplements (HDS), to minimize adverse reactions. Education 
can be difficult in many clinical settings due to time and personnel constraints. This 
document will review the feasibility of alternative education strategies in clinical settings 
to improve patient knowledge independent of extensive clinician management. Self-
learning, DVD-based education strategies may effectively increase patient knowledge 
regarding HDS intake, and further research is warranted to examine its routine use in 
clinical settings.  
 
Summary 
 
 Atrial fibrillation (AF) is a common cardiac arrhythmia that significantly impacts 
the health of many aging adults.1-4 Pharmaceutical therapies, such as warfarin, are 
essential for effective disease management, but these drugs are frequently sited as a major 
factor for morbidity due to their narrow therapeutic index and the significant adverse 
effects that may occur when anticoagulation therapies are out of range. Patients must 
understand the many factors that influence International Normalized Ratio (INR) values 
to decrease medication variability and to improve patient outcomes.4-6 Similarly, an 
effective education tool must be implemented to increase patient knowledge regarding 
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environmental factors that can contribute to poor warfarin control while minimizing 
clinical healthcare burdens in a time of shrinking financial and human resources.7  
 Of these influencing factors, herbal and dietary supplement (HDS) intake is 
associated with suboptimal coagulation control.8-9 Though knowledge regarding HDS 
management is essential to minimize unintended INR variability, there is limited research 
regarding patient understanding of HDS-warfarin interactions.8-11 The select studies that 
have explored HDS-warfarin management show patients have poor understanding of 
these factors and their influence on warfarin control. 8-11 Also, alternative education 
strategies have not been explored to routinely to educate AF patients regarding specific 
disease and medication management.  
 
STUDY OBJECTIVES AND FINDINGS 
This study aimed to develop an education tool that could increase patient 
knowledge of HDS-warfarin control independent of extensive clinician time. A self-
learning, DVD-based format was chosen for its validated effectiveness in chronic disease 
education, the minimal cost to developers and care providers, and the reduced time 
required by clinicians to educate patients. An equivalent one-on-one education program 
was created to serve as a control for the alternative education outcomes (please see 
appendices A-H for education materials and testing data).  Researchers also hoped to 
obtain INR values of study participants to determine if this education could improve 
warfarin control.  
A 120-participant pilot study was conducted in collaboration with the 
Intermountain Rhythm Specialty Clinic in Murray, Utah. This population was chosen as 
patients on warfarin routinely receive education in similar outpatient venues where INR 
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values are being monitored. Researchers felt if the proposed alternative education 
modalities could effectively increase patient knowledge regarding HDS-intake strategies 
while reducing needed clinician time for one-on-one education, these tools could be more 
extensively researched and implemented in clinics to improve warfarin-associated 
outcomes.    
 The findings from this research study are consistent with the current literature and 
provides additional evidence that patients routinely consume HDS products, but have 
limited knowledge regarding HDS-warfarin interactions and management.8-11 Although 
our study did not show patients could routinely recall all products that interact with 
warfarin, patients did state increased understanding that these products do interact with 
coagulation therapies, and the majority understood their healthcare provider must be 
aware of HDS intake to minimize unintended INR variability.   
This study found education provided in a self-learning, DVD-based format had 
similar efficacy when compared to one-on-one teaching methods. These findings add to 
current literature regarding warfarin and chronic disease management because alternative 
education stratagems have not been statistically validated to increase patient knowledge 
regarding warfarin interactions.  
 
STUDY LIMITATIONS 
A large limitation of the DVD-based education was there was limited space in the 
clinic to allow participants to view the DVD; therefore, participants were asked to view 
the DVD in their home, and researchers followed up via telephone. Continued 
participation engagement was difficult, and follow-up to receive only 35% DVD-based 
participant completion took extensive time. This education modality can only be effective 
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if patients view the DVD, and in-home viewing requires high patient engagement and 
motivation. Therefore, this education format may be more successful if the education was 
provided to a captive audience, for example, in office waiting rooms or while patients are 
waiting for the clinician.  
Researchers did obtain INR statistics for study participants (Table 4-1) during the 
course of the study, but field experts including the collaborating physician and lead 
pharmacist felt the research model did not account for other factors that could influence 
INR variability. These factors could include: nutritional status, availability of both dietary 
and endogenous sources of vitamin K, genetic polymorphisms, hepatic function, 
medication clearance, intestinal absorption, schedule compliance, drug interactions, and 
herbal and dietary supplement intake; therefore, this measure was not used as an 
indication of efficacy of the education models tested. 7, 2-16 
 Further research should be done to determine if DVD-based education could 
increase patient knowledge regarding medication-associated factors and show-validated 
improvement in medication safety (i.e. INR data).  Future study methods must account 
for other influencing factors to provide statistical power to this measure.  
 
Table 4-1. Participant INR Values During Education Intervention, n (%) 
Total INR Values Collected 974 
Below Therapeutic range 215 (22) 
In Therapeutic Range 588 (60) 
Above Therapeutic Range 171 (18) 
 
 
Conclusions 
 
Patients must know how to account for influencing medical factors for disease 
and medication safety, and healthcare providers must have effective education tools to 
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address these knowledge deficits.17-20 This study showed self-learning, DVD-based 
strategies can address patient knowledge and provide an acceptable education method for 
clinical settings. Although further research is needed to determine the most effective way 
to implement these tools in clinical settings, these research findings show DVD-based 
education strategies are an effective tool for the elderly chronic disease population. These 
findings may be useful even as new mediations and disease management approaches 
enter the healthcare industry as chronic disease prevalence is rising in an aging US 
population.21 Teaching strategies must be robust and effective to address knowledge 
deficits in these populations.17-20 
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APPENDIX A.  PRE-TEST AND POST-TEST 
 
Identification Number: _________________ 
 
1. Why is it important to take your warfarin every day? 
a. To prevent a heart attack 
b.  To prevent blood clots 
c.  To control blood pressure  
 
2. What should you do if you forget to take your warfarin? 
a. Take your dose as soon as you remember 
b. Double up on your warfarin 
c. If it has been less than 12 hours, take your warfarin dose  
 
3. What is a supplement? 
a. A vitamin or mineral  
b. A product that can be used instead of eating foods 
c.  All of the above  
      
4. What is an herbal product?  
a. A product that is made from a natural source to provide functional support 
b. A product that can be used instead of eating foods 
c. A product that is only made in tablet form 
 
5. What can happen if you use herbal or dietary supplements while you are taking 
warfarin? 
a. Stroke or bleeding  
b.  A heart attack  
c. Change in heart rhythm   
 
6. Which of the following should not be used while taking warfarin without first 
discussing this with your health care provider? (Please circle all that apply.) 
a. Fish oil    
b. Glucosamine 
c. Coenzyme Q 10 
d. Green tea 
e. Any product containing 
vitamin K  
f. Ginger  
g. Spices used in cooking 
h. Iron  
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Please use the label below to answer questions 7-8. 
 
7.  Which of the following nutrients listed in the label may interact with warfarin?  
a. Copper 
b. Iron  
c.  Folic Acid 
d. Vitamin A 
 
8. Taking this supplement while using warfarin could: 
a. Increase your risk of bleeding or having a stroke 
b. Increase your risk of a heart attack 
c. Have no effect on your warfarin medication 
 
9. You should speak to your doctor: 
a. Before taking any new supplement or herbal product 
b. If you make any changes to what supplement or herbal product(s) you are 
already taking 
c. If you stop taking a supplement or herbal product 
d. A and B 
e.   All of the above 
 
 
 
 
 
 
 
 
Supplement Facts 
Serving Size 1 tablet 
Suggested Use: Adults, take one tablet per day with meal 
Amount per serving                           % Daily Value 
Folic Acid 600 mcg 100 
Vitamin K 160 mcg 200 
Vitamin A 500 I.U. 100 
Vitamin D 400 I.U. 100 
Vitamin B 12 4 mcg 66 
Iron 18 mg 100 
Copper 1 mg 50 
Ingredients: Vitamin A acetate, folic acid , menoquinone, vitamin D, 
vitamin B12, ferrous iron, copper sulfate 
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Post- test only question: 
 
10.  Because of this education, I will (please circle all that apply): 
a. Stop taking any supplements or herbal products 
b.  Read a supplement facts label before taking supplements or herbal products 
c. Talk to my doctor or pharmacist about the supplements I am currently taking  
d. Talk to my doctor or pharmacist before taking any new supplement or herbal 
product 
e. Continue not to take any supplements or herbal products 
f. Continue to take the supplements and herbal products I was taking before the 
education  
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APPENDIX B. INFORMED CONSENT 
 
 
Patient authorization and consent to participate in a research study 
 
DVD (Self Learning) Versus Traditional Education Approaches to Improve The Safety 
Of Warfarin Anticoagulation Therapy In Patients With Atrial Fibrillation 
 
Principal investigator:  Thomas Jared Bunch MD 
Sub-investigators: Jessica Oliver RD 
Sponsor and Location: Intermountain Healthcare 
 
Dr. Jared Bunch, MD, in collaboration with Utah State University, is conducting a 
research study to find out more about supplement use in patients with atrial fibrillation 
who are on warfarin.You have been asked to take part in this study because you have 
atrial fibrillation and are currently taking warfarin.The purpose of this consent form is to 
provide you with information you and your family need to make an informed decision 
whether to take part in this study. 
Why is this study being done? 
 
The purpose of this research study is to educate patients about some of the risks of using 
supplements while they are on warfarin. By informing patients about how to 
appropriatley consume supplements, patient safety will likely be increased.  
How many people will take part in this study? 
150 patients will be enrolled in this study through the Coumadin Clinic at Intermountain 
Medical Center in Murray, Utah.   
 
What is involved in this study? 
 
Study Procedures 
If you agree to participate in this study, you consent to: 
1. Complete an initial demographic questionnaire and pre-test to assess your current 
knowledge concerning warfarin and supplements and herbal products.  
2. Participate in a one-on-one education, a group class, or view an educational DVD 
concerning supplement use and warfarin.  
3. Complete a post-test immediately following the education.  
4. Three months following the education, you will be contacted via telephone to re-
administer the post-test. This will help researchers see how much information 
taught was helpful and remembered. 
5. Grant researchers permission to look at your past medical records to record your 
INR levels for three months before and after you participate in the study.  
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What are the risks of this study? 
 
Participating on this study may involve some added risks or discomforts. These include: 
loss of personal time from completing the education and telephone calls, an inadvertent 
disclosure of personal information. These risks will be minimized by following 
confidentiality protocols as listed below, and ensuring the education and telephone calls 
will be conducted by competent, capable instructors to minimize time required by you as 
the participant. 
 
How long will I be in the study? 	  
You will participate in this study for three months. The investigator may decide to take 
you off the study at any time if he/she feels your continued participation would in any 
way impair your health. 
 
What are the benefits to taking part in the study? 
 
Possible benefit to you 
There may be a direct benefit to you from participating in this study by increasing your 
knowledge about supplements, herbal products, and warfarin.  
 
Potential benefit to others 
Your participation in the education may help future patients who are placed on warfarin 
by providing investigators more information about the type of education patients need 
about warfarin and supplements. This information will allow investigators to provide an 
educational tool to other patients with atrial fibrillation to help these individuals safely 
consume supplements and warfarin.  
 
What other options do I have? 
 
Instead of being in this study, you have the option to not enroll in this study. 
 
What are the costs? 
 
• You will not be charged to enroll in this study. 
• You or your insurance carrier will be billed in the usual manner for the normal 
standard of care patients with your condition(s) would receive if hospitalized for 
medical conditions not directly related to participation in this registry.  This 
includes your hospital room charges, routine tests and procedures, medications, 
and any follow up visits you may need after you are discharged from the hospital. 
If your medical insurance does not pay for your care you will be responsible for 
the cost of the medical care related to your condition including but not limited to: 
laboratory tests, deductibles, co-payments, physician and clinic fees, 
hospitalization and procedures.  
• You will not be paid for participating in this study.  
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What if I get hurt or ill from my participation? 
 
As a research subject, you may be harmed as a result of your participation. It is the nature 
of medical research that all adverse events are not preventable or foreseeable. In the event 
you sustain injury resulting from your participation in the research project, Intermountain 
Healthcare can provide to you, emergency and temporary medical treatment and will bill 
your insurance company.  Since this is a research study, payment for any injury resulting 
from your participation in this research study may not be covered by some health 
insurance plans. 
 
If you believe that you have sustained an injury as a result of your participation in this 
clinical investigation, we ask that you contact the investigator as soon as possible. You 
may also contact the Office of Research at (1-800) 321-2107. 
 
What about confidentiality? 
 
Study records that identify you will be kept confidential as required by law. Federal 
Privacy Regulations provide safeguards for privacy, security, and authorized access. 
Intermountain Healthcare has a commitment to protect your confidentiality. Federal 
regulations require that you understand how your protected health information (PHI) is 
used for this study. 
 
This is the information we will use:   
 
 Your initials may be attached to a study identification code (for example ABC-123). 
 Your name, initials, date of birth, address and telephone number(s) will be 
placed into a study document entitled “confidential enrollment log”.  This log is not 
available to anyone except Intermountain Healthcare staff members who are 
conducting this clinical trial at Intermountain Medical Center.  There are several 
reasons investigators keep the confidential enrollment log:  
• We may need to contact you with information regarding the trial or results of 
the trial after your participation has ended and/or regulatory agencies may 
request to examine all records generated during a clinical trial. 
 
 Your family medical history may be reviewed to assess risk factors that may affect 
your eligibility to participate in this trial. 
 
 Your previous medical history may be reviewed to determine your eligibility to 
participate in this trial. Hospital admission and discharge summaries placed in your 
hospital chart(s) give us the most reliable information. 
 
 Your most current medical history or information specific to the condition for 
atrial fibrillation may be reviewed to determine your eligibility to participate in this 
trial. Hospital admission and discharge summaries placed in your hospital chart(s) 
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give us the most reliable information. 
  
 Current and past medications or therapies/results which may affect your eligibility 
for this trial or your safety while participating in it may be reviewed to determine 
your eligibility to participate in this trial. 
 
 Information (results) from tests, procedures and physical examinations, such as 
blood pressure readings, heart rate, breathing rate, and temperature at specified 
times, may be reviewed for the purpose of establishing your baseline condition and 
to continue monitoring your progress and/or safety while participating in this trial. 
 
 We may need to review your prior medical history (PMI)/medical records kept by 
other physicians you may see for your medical conditions(s) to establish eligibility, 
to document any adverse events/side effects you may have during the trial and to 
assure that you can safely participate in this trial. If this information is needed we 
will ask you to give us permission to ask your doctor for it by signing a medical 
release of information form. 
 
   Dates of surgeries, device implants, or procedures related to this clinical trial.  
 
   The results of this research study may be presented at meetings or in publications.  
Your identity will not be disclosed in those presentations. 
 
Others who will have access to your identifiable PHI for this research project include:  
(Intermountain Healthcare) Intermountain Medical Center’s Institutional Review Board 
(the committee that oversees research studying people) and authorized members of 
Intermountain Healthcare’s workforce who need the information to perform their duties 
(for example: provide treatment, to ensure integrity of the research, and for accounting or 
billing matters),  the Food and Drug Administration (FDA), and others as required by 
law. 
 
Except as addressed in this authorization form, you will not be identified by name, social 
security number, address, telephone number, or any other direct personal identifier in 
study records disclosed outside of Intermountain Healthcare. Information received during 
the study will not be placed on any mailing lists or sold to anyone for marketing 
purposes. For records disclosed outside of Intermountain Healthcare, your information 
will be assigned a unique code number (for example 123-ABC). The key to the code will 
be kept in a password protected file stored in the Intermountain Healthcare computer 
network.   
 
Signing this document means you allow us, the researchers in this study, and others 
working with us to use PHI about your health for this research study.  You can choose 
whether or not you will participate in this research study; however, in order to participate 
you have to sign this consent form.  
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You may change your mind later, and ask us to stop using or disclosing your PHI.    You 
must either give this notice, called a revocation, in writing to the principal investigator, 
Thomas Jared Bunch MD, the principal investigator’s staff, or mail it to Thomas Jared 
Bunch MD c/o Cardiology Department, Intermountain Medical Center, 5121 South 
Cottonwood Street, Murray, UT 84157-7000. If you revoke this authorization, we will 
not be able to collect new information about you, and you will not be able to participate 
in the study; however, we can continue to use information we have already started to use 
in our research, as needed to maintain the integrity of the research.  
 
If we send PHI about you outside Intermountain Healthcare, based on this or any other 
authorization you sign, we cannot guarantee that the recipient will not redisclose your 
PHI to a third party. The recipient of the information may not be required to abide by this 
authorization or applicable federal and state law governing the use and disclosure of your 
PHI. 
 
You have a right to information used to make decisions about your health care; however, 
your information from this study will not be available to you during the study. It will be 
available after the study is finished and the results are made available. This authorization 
does not have an expiration date.  
 
If I agree to participate what are my responsibilities? 
 
We would expect that you, as a patient at Intermountain Medical Center and as a study 
participant in the trial, would have the following responsibilities: 
• You will keep your scheduled clinic visits with your doctors. 
• It is very important you discuss taking over-the-counter medications with your 
study doctor.  This includes common over-the-counter medications you may not 
think important to mention to your physician such as headache or cold remedies. 
• You will also be asked to review any other medications you may have taken since 
your last visit. 
• If you decide you no longer wish to participate in this study, you will notify your 
doctor or coordinators immediately so that that we can adjust your care 
appropriately.  
What are my rights as a participant? Where can I get more information? 
A copy of this form will be given to you as a participant in this study if you agree to enter 
the study.   
 
Taking part in this study is your choice and your participation is voluntary. If you agree 
to take part and then decide against it, you can withdraw for any reason. If you decide to 
stop taking part in the study, you should talk to the researcher so it can be done safely.  
Leaving the study will not result in any penalty or lost benefits to which you are 
otherwise entitled and the medical care you receive will not be affected in any way. 
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If you have any questions now or at any point during the study concerning the research 
or related matters, or, if you think you have had study related injury, you should 
call the principal investigator, Thomas Jared Bunch MD at (801) 507-4701 (24 
hour voicemail).  
 
If you would like to speak to someone not associated with the study about your rights as a 
participant, or any other matter related to clinical research conducted at Intermountain 
Healthcare facilities, contact the Intermountain Healthcare Office of Research at (1-800) 
321-2107. 
 
Sometimes during the course of a research project, new information becomes available 
about the treatment/drug/procedure/data that is being studied or there is a change in the 
trial protocol (directions on how to conduct the trial). If this happens, your research 
doctor will tell you about how it will affect your participation in the trial and discuss with 
you whether you want to continue in the study.  If you decide to withdraw from study 
treatment, the investigator will make arrangements for your care to continue.  If you 
decide to continue in the study, you will be asked to sign an updated consent form, which 
will contain the new information. (You may sign more than one consent document 
throughout the duration of the trial.) Also, upon receiving new information the 
investigator might consider it to be in your best interest to withdraw you from 
participation in the study. He/she will explain the reasons and arrange for your care to 
continue. 
 
For more information about my rights to my PHI, how to revoke this authorization, and 
how (Intermountain Healthcare) Intermountain Medical Center uses my health 
information, I may ask to see or obtain a copy of the Intermountain Healthcare Notice 
of Privacy Practices.  I hereby acknowledge that I have received or been offered a 
copy of Intermountain Healthcare’s Notice of Privacy Practices.  
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Signatures 
 
My signature below indicates that I have read or had read to me and understand all of the 
information given to me in this document. The information in this document has been 
explained to me and I have had the opportunity to ask questions.  My signature below 
indicates that I voluntarily agree to participate in the study described in this document 
and I have received a copy of my signed/dated consent. 
 
 
 
 
 
 
If the patient is unable to give consent and authorization, consent and authorization is 
given by the following authorized personal representative of the individual: 
  
_________________________ 
Name of authorized personal representative 
 
__________________________    _____________ 
Signature of authorized personal representative    date 
 
If the participant is unable to give authorization and consent, describe the legal 
representative’s authority to act for the individual. ___________________________ 
 
I, the undersigned, certify that I have fully explained this clinical investigation to the 
patient (and to the patient’s legal/personal representative(s), if the patient wishes) signing 
this consent form and the patient/representative (if applicable) has been given the 
opportunity to ask questions regarding the contents of this consent form and the 
expectations associated with his/her participation in this research study. 
 
 
______________________________     ________________     
Signature of person obtaining consent                     date        
 
 
  
________________________	  	  	  	  	  	  	  	  __________________________	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ___________	  
patient’s printed name                                  patient’s signature                                          date                             	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APPENDIX C. ONE-ON-ONE AND GROUP HDS-WARFARIN CURRICULUM 
 
Objectives: 
1. Participant will provide one reason why compliance with warfarin therapy is 
critical.  
2. Participant will verbalize what to do if a warfarin dose is missed.  
3. Participant will define HDS.  
4. Participant will identify three risks associated with HDS use while on warfarin 
therapy.  
5. Participant will identify three commonly used HDS that interact with warfarin.  
6. Participant will identify and interpret three components of a supplement label.  
7. Participant will verbalize the importance of consulting with a health care provider 
prior to: 
a. Continuing use of any HDS while on warfarin. 
b. Beginning any new HDS therapy.  
c. Making any changes to current HDS regimen.  
Total Time: 20-25minutes 
 
Materials needed: 
• Attached handout entitled “Commonly Used Supplements and Herbal Products 
that May Interact with Warfarin”. 
• Attached handout detailing how to interpret a supplement label. Additionally, you 
may show the participant an actual supplement containing vitamin K to discuss 
during objective six. 
• The pre- and post-test to administer to the participant. 
 
Introduction and Pre-test  
 
Time: 2 minutes 
 
Thank the participant for volunteering to participate in this education. 
 
Explain to the participant: 
• The purpose of this education is for you to learn more about warfarin and the risks 
associated with using HDS products while on warfarin.  
• Although all supplements and herbal products are not dangerous, many interact 
with warfarin and should be avoided and/or used with caution.  
• The purpose of the pre-and post-test is to determine if my instruction is effective.  
Verbally administer the pre-test to the participant. You may clarify questions but you 
may not provide answers to the participant.  
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Invite the participant to ask any questions about supplements and warfarin during the 
course of the education. 
 
Objective 1: Participant will be able to state why compliance to warfarin is critical.  
 
Time: 2 minutes 
 
Ask the participant: Why is it important to always take warfarin as prescribed by your 
doctor? 
 
Explain to participant: 
• Warfarin helps prevent blood clots. Common types of blood clots include deep 
venous thrombosis clots in your leg or a pulmonary embolism (a clot in your 
lungs). Blood clots can cause a stroke. If you at risk for a stroke, your doctor 
might prescribe you warfarin. Warfarin does not prevent heart attacks or affect 
your heart rhythm or blood pressure.  
• If you miss a dose, or do not take warfarin as directed, your risk for stroke 
increases. If you double your dose, your risk for bleeding increases.   
• Your doctor can monitor if warfarin is working correctly by testing your International 
Normalized Ratio (INR), which is also known as your blood warfarin level.  
 
Objective 2: Participant will verbalize what he/she should do if a warfarin dose is 
missed.  
 
Time: 2 minutes 
 
Ask the participant: What should you do if you miss a warfarin dose?  
 
Explain to the participant:  
• Warfarin is only taken once a day. If you forget to take your dose, but remember 
within 12 hours of when you were supposed to take your warfarin, take your dose 
at that time. Take your next dose of warfarin (the following day) as you normally 
would.  
• If it has been more than 12 hours since you were supposed to take your warfarin, 
skip that daily dose and take your warfarin the next day as you normally would.  
• For example: if you are supposed to take your dose at 9:00 am and you remember 
at 1:00 pm (4 hours later), it is okay to take your warfarin at 1:00 pm and then 
take your next dose of warfarin the next day as you normally would. However, if 
you remember at 10:00 pm (13 hours later) do not take your warfarin at 10:00 pm, 
but take it the next day as you normally would.  
• DO NOT double up on your warfarin dose even if you have skipped a dose. This 
may lead to bruising, bleeding, or even death.  
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• If you notice any signs of increased bruising or bleeding, contact your medical 
professional immediately.   
• If you miss more than one dose, contact your health care provider. 
 
Objective 3: Participant will define what an HDS product is.  
 
Time: 2 minutes 
 
Ask the participant: What is the difference between a supplement and an herbal product? 
Explain to the participant:  
• A supplement can be a vitamin, mineral or a combination of these. Supplements 
should not replace food. 
• Examples of supplements include: 
o A multivitamin  
o Any individual vitamin or mineral (vitamins A,C, and K, magnesium, etc.) 
 
• An herbal product is a product made from a natural source that may contain 
vitamins, minerals, and other products including fish oils, botanicals or other 
naturally occurring compounds. Herbal products can be in capsule, teas, drinks, or 
powder form. Herbal products are often used to provide functional support.   
• Examples of herbal products include: 
o Green tea  
o Evening Primrose Oil 
o Ginger tablets 
o Garlic pills  
! Ginger and garlic are safe to use as spices in cooking.  
 
Objective 4: Participant will identify three risks associated with HDS product use while 
taking warfarin. 
 
Time: 3 minutes  
 
Ask the participant: What are the risks of using supplements or herbal products when 
taking warfarin? 
 
Explain to the participant: 
• Although patients commonly use HDS products, many interact with warfarin. 
This may lead to:  
o Bruising or bleeding 
o Stroke or clots, such as: 
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! Deep vein thrombosis (DVT), which is a clot usually found in the 
leg  
! Pulmonary Embolism (PE), which is a clot usually found in the 
lungs 
• It is important to know that your INR level will not always tell you if the HDS 
product you are taking has affected how well warfarin is working in your body. 
Before taking any HDS product, please ask your doctor or pharmacist if the 
product is safe to use while taking warfarin.  
 
Objective 5: Participant will identify three commonly used supplements and/or herbal 
products that interact with warfarin.  
 
Time: 5 minutes 
 
Explain to participant:  
• We don’t know a lot yet about which supplements and herbal products are safe to 
use when taking warfarin.  
• We will now talk about a few of the most popular supplements and herbal 
products on the market today and whether or not they interact with warfarin.  
Give participant the supplement handout entitled “Commonly Used Supplements and 
Herbal Products that May Interact with Warfarin” and discuss this handout with the 
participant.  
 
These supplements and herbal products have been broken down into 3 categories:  
1. HDS products that interfere with warfarin.  
2. HDS products that interact with warfarin.  
3. HDS products that we are unsure of their interaction or may have a small 
interaction with warfarin.  
No matter what, if you are taking an HDS product or are thinking about it, you need to 
contact your health care professional before beginning or stopping use of any HDS 
product.    
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1. Supplements and herbal products 
that interfere with warfarin. 
• Baldo 
• Garlic  
• Ginseng 
• St. John’s Wort 
• Wintergreen 
• Gingko 
• Green tea 
• Vitamin K 
2. Supplements and herbal products 
interact with warfarin.  
• Vitamin A 
• Vitamin D 
• Vitamin E 
• Coenzyme Q10  
• Glucosamine 
• Carnitine 
• Melatonin 
• Chondroitin 
• Cranberry 
3. Supplements and herbal products 
that may have a minor interaction 
with warfarin and should be used 
with caution and only with the 
approval of a health care 
professional.   
• Soy 
• Chelation therapy 
• Ginger 
• Grapefruit 
• Cod liver oil  
 
 
 
 
Explain to the participant: 
• There are many HDS products that are not listed in this handout. However, that 
does not mean that they are safe to take while taking warfarin. Contact your 
doctor or pharmacist before beginning ANY supplement or herbal product. 
 
Objective 6: Participant will be able to identify and interpret three components of a 
supplement label. 
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Time: 5 minutes 
 
Show participant the supplement label handout while discussing the components of a 
supplement label.  
 
Points to discuss: 
• Amount per serving: This column lists all nutrients in the product and the quantity 
of each nutrient.  
• Ingredients: All nutrients and all other ingredients contained in the product can be 
found in the ingredient list and in the amount per serving column. 
• You should look at both the amount per serving and the Ingredients column to see 
if the HDs product contains anything that could interact with warfarin.  
o For example: If Baldo, Vitamin K, green tea, and glucosamine were listed 
in either location, you should not take that supplement until you talk to 
your doctor or pharmacist to make sure it is okay to use, and, if so, how to 
take it safely.    
• Serving Size: This is the manufacturer’s recommended serving. 
• Percent Daily Value: This number is the percentage of the recommended amount 
of each nutrient in the supplement. If an asterisk(*) is present, a recommended 
amount has not been set for that specific nutrient.  
 
Ask the participant: 
• Now that you are familiar with a supplement facts label, let’s look at the label and 
determine whether this supplement contains ingredients that may interact with 
warfarin.  
Supplement Facts 
Serving Size 1 tablet 
Suggested Use: Adults, take one tablet per day with meal 
Amount per serving                           % Daily Value 
Folic Acid 600 mcg 100 
Vitamin K 160 mcg 200 
Vitamin A 500 I.U. 100 
Vitamin D 400 I.U. 100 
Vitamin B 12 4 mcg 66 
Iron 18 mg 100 
Copper 1 mg 50 
Ingredients: Vitamin A acetate,  folic acid , menoquinone, vitamin D,  
vitamin B12, ferrous iron, copper sulfate 
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Explain to the participant: This supplement contains vitamins K, A, and D. All of these 
vitamins can interact with warfarin, and should be used with caution, but vitamin 
K is of special concern. Vitamin K helps blood clot in the body. It is important to 
know that just because you are taking warfarin, it does not mean you don’t need 
vitamin K. However, taking too much vitamin K, especially from supplements, 
may increase your chance of a stroke. Please talk to your doctor or pharmacist 
before taking vitamin K or any supplement containing vitamin K. It is important 
to note that it may be possible to take these supplements ONLY if you take them 
consistently and you have discussed them with your health care professional. 
 
Objective 7:  Participant will verbalize understanding of the need to consult with his/her 
health care provider before: 
a. Continuing use of any HDS product while on warfarin. 
b. Before taking any new HDS product.  
c. Making any changes to your current HDS product regimen.  
Time: 2 minutes 
 
Explain to the participant: 
• Because HDS products may cause warfarin to not work properly, you should talk 
to your health care provider before: 
o Continuing use of any HDS product. 
o Before taking any new HDS product. 
o Making any changes to your current HDS product regimen. 
 
Closing and Post-test 
 
Time: 5minutes  
 
Reinforce with participant: 
• Talk to your health care provider about any HDS products that you are currently 
taking or that you may wish to take.  
• It is possible to take HDS products safely if you:    
o Take them consistently 
o Take the same brand/manufacturer 
o Tell your healthcare professional if you start or stop using HDS products.   
• It may be a good idea to bring any HDS product you are taking with you to your 
next doctor visit so he/she can help you decide if it is okay to take while using 
warfarin.   
Administer the post-test. You may verbally give the test or allow the participant to 
complete it independently. You may clarify questions but you may not provide answers 
to the participant. Thank the participant for participating in this education. 
Collect the pre-and post-test and place in provided folder to return to research team.  
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APPENDIX D. ONE-ON-ONE EDUCATION HANDOUTS 
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How to Read a Supplement Facts or Herbal Product Label 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 To find out if a supplement or herbal product is safe to use while you are taking 
warfarin, you need to look at both the amount per serving column and the ingredient 
list.  Then, look at the handout given to see if the supplement or herbal product is safe to 
use while taking warfarin. 
 
 
 
 
 
 
Supplement Facts 
Serving Size 1 tablet 
Suggested Use: Adults, take one tablet per  
day with meal. 
Amount per serving              % Daily Value 
Folic Acid 600 mcg 100 
Vitamin K 160 mcg 200 
Vitamin A 500 I.U. 100 
Vitamin D 400 I.U. 100 
Vitamin B 12 4 mcg 66 
Iron 18 mg 100 
Copper 1 mg 50 
Ingredients: Vitamin A acetate,  folic acid, menoquinone, 
vitamin D,  
vitamin B12, ferrous iron, copper sulfate The	  Ingredients	  lists	  everything	  contained	  in	  the	  supplement.	  	  
Percent	  Daily	  Value	  (DV)	  is	  the	  percentage	  of	  the	  recommended	  amount	  of	  each	  nutrient	  in	  the	  supplement.	  	  If	  an	  *	  asterisk	  is	  present	  in	  this	  column,	  it	  means	  that	  a	  recommended	  daily	  allowance	  has	  not	  been	  made	  yet	  for	  that	  nutrient.	  
Serving	  Size	  is	  the	  manufacturer’s	  recommended	  serving.	  	  
The	  Amount	  per	  Serving	  column	  lists	  all	  nutrients	  and	  their	  amount	  per	  serving	  in	  the	  supplement.	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Commonly Used Supplements and Herbal Products that Can Interact with Warfarin 
Stop: These products interfere with warfarin. Talk to your health care professional before 
taking any of these products.
• Baldo 
• Dansen 
• Dong 
• Quai 
• Garlic 
  
• Gingko 
• Ginseng 
• Green tea 
• St. John’s Wort 
• Wintergreen
Caution: These interact with warfarin.  It is important to talk to your health care 
professional before taking any of these products. 
 
• Vitamin A 
• Vitamin D 
• Vitamin K 
• Vitamin E 
• Carnitine 
• Chondroitin 
• Coenzyme Q10 
• Evening Primrose 
Oil 
• Glucosamine 
• Melatonin 
 
Yield : These products have an unknown interaction with warfarin. It is important to talk 
to your health care professional before taking any of these products. 
 
• Chelation therapy 
• Cod liver oil 
• Ginger 
• Grapefruit 
• Fish oil  
• Soy 
  
Note:	  Many	  supplements	  and	  herbal	  products	  are	  not	  listed	  on	  this	  handout.	  However,	  that	  does	  NOT	  mean	  that	  they	  are	  safe	  to	  use	  while	  taking	  warfarin.	  Talk	  to	  your	  health	  care	  professional	  before	  using	  ANY	  new	  supplement	  or	  herbal	  product.	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What I Need to Know About Warfarin 
 
What	  does	  warfarin	  do?	  
•  Warfarin	  helps	  prevent	  blood	  clots.	  Blood	  
clots	  can	  lead	  to	  stroke	  or	  heart	  a9ack.	  	  
•  In	  order	  for	  warfarin	  to	  help	  prevent	  blood	  
clots,	  you	  must	  take	  it	  as	  prescribed	  by	  your	  
doctor.	  
•  Your	  doctor	  can	  check	  how	  well	  your	  
warfarin	  is	  working	  by	  looking	  at	  your	  
InternaAonal	  Normalized	  RaAo	  (INR).	  	  
•  Warfarin	  is	  working	  best	  when	  your	  INR	  is	  
between	  2	  and	  3.	  
Why	  must	  I	  take	  warfarin	  every	  
day?	  	  
•  If	  you	  miss	  a	  dose,	  or	  do	  not	  take	  warfarin	  
as	  recommended,	  your	  chance	  for	  stroke	  or	  
heart	  a9ack	  is	  higher.	  
•  If	  you	  double	  up	  on	  a	  dose,	  your	  chance	  of	  
bleeding	  is	  higher.	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What	  do	  I	  do	  if	  I	  miss	  a	  warfarin	  dose?	  
•  Warfarin	  is	  usually	  taken	  once	  a	  day.	  	  
•  If	  you	  forget	  to	  take	  your	  dose,	  but	  remember	  within	  12	  
hours	  of	  when	  you	  were	  supposed	  to	  take	  your	  
warfarin,	  take	  your	  dose	  at	  that	  Ame.	  
•  If	  it	  has	  been	  more	  than	  12	  hours	  since	  you	  were	  
supposed	  to	  take	  your	  warfarin,	  do	  not	  take	  that	  dose.	  	  
•  Resume	  taking	  your	  warfarin	  medicaAon	  at	  the	  normal	  
Ame	  the	  next	  day.	  	  
•  DO	  NOT	  double	  up	  on	  you	  warfarin	  dose.	  	  
•  If	  you	  miss	  more	  than	  one	  dose,	  contact	  your	  health	  
care	  provider.	  
When	  should	  I	  talk	  to	  my	  health	  care	  
provider	  about	  supplements	  and	  herbal	  
products?	  
•  Because	  supplement	  and	  herbal	  products	  can	  interact	  
with	  warfarin,	  you	  should	  talk	  to	  your	  health	  care	  
provider	  before:	  
•  ConAnuing	  to	  use	  any	  supplement	  or	  herbal	  product	  
•  Before	  taking	  any	  new	  supplement	  or	  herbal	  product	  
•  Making	  any	  changes	  to	  your	  current	  supplement	  or	  
herbal	  product	  regimen	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APPENDIX E. DVD-BASED CURRICULUM SLIDES AND SCRIPT 
 
 
 
 
 
Slide 1 Script: Hello. You are watching this video because you take the medicine, 
warfarin. Warfarin, also known as coumadin, is a life-saving medication. However, 
taking it is not without risks. In the next few minutes, we will review some of the most 
important things you need to remember while taking warfarin. Then, we will discuss 
some basics about supplements and herbal products so you can take them safely while 
you are on this medication. 
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Slide 2 Script: Warfarin helps prevent blood clots. Blood clots can occur in your legs, 
lungs, and arteries. These blockages can cause a stroke, heart attack, or tissue death. If 
you are at risk for a stroke, your doctor may prescribe warfarin. Warfarin does not 
prevent heart attacks, affect your heart rhythm, or increase your blood pressure.  
 
 
 
 
 
Slide 3 Script: If you miss your dose of warfarin, or do not take warfarin as directed, your 
risk for stroke increases. If you double your dose of warfarin, your risk for bruising or 
bleeding increases. This is why it is important to always take warfarin as prescribed by 
your health care professional. 
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Slide 4 Script:  Your doctor can check to see if warfarin is working correctly by testing 
your International Normalized Ratio, or INR, which is also known as your blood warfarin 
level.  
 
 
 
 
 
Slide 5 Script: Your INR level can be influenced by many factors including:  
 
Your compliance to your warfarin prescription, the foods you eat, the medications you 
take, the alcohol you may consume, and the herbal and dietary supplements you use.  
 
Making any major lifestyle changes as outlined in this list could increase your clot or 
stroke risk.  
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Slide 6 Script: An increase in your INR leads to delayed blood clotting. If your INR is too 
high, you may experience abnormal bruising and bleeding.  A slight increase in bruising 
can occur while you are on this medication. However, excessive bruising is problematic 
and should be addressed by your health care professional.  
 
You  will also need to monitor for any signs of excessive bleeding. For example, if you 
receive what seems to be a minor injury that does not stop bleeding, your INR may be too 
high. Furthermore, be particularly cautious to avoid falls that may lead to more serious 
injuries, including internal bleeding.  
 
The major sign of internal bleeding is blood in your stool. Although you may not notice 
this sign after a fall, bleeding may still have occurred. Either way, be sure contact your 
health care professional immediately. 
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Slide 7 Script: A decrease in your INR may result in a blood clot which usually originates 
in your leg or another large vein or artery. Clots are very dangerous because they can 
move to your lungs or brain and cause a stroke.  
 
Signs of clot formation include: an abnormally swollen, warm, flushed, or discolored area 
of skin. This usually happens very quickly and is most commonly found in the leg or 
pelvis. If you ever notice these dangerous symptoms, please contact your doctor 
immediately.  
 
 
 
Slide 8 Script: Your healthcare team is constantly watching for signs that you are at an 
excessive risk for stroke.  
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Slide 9 Script: Your health care team is constantly watching for signs that you are at an 
excessive stroke risk. Unfortunately, it is not always possible to prevent all strokes. 
Therefore, you need to know the symptoms of a stroke.    
 
Signs that you may have experienced a stroke include:  
• Sudden numbness or weakness, particularly on one side of your body,  
• confusion or trouble speaking,  
• troubles with balance, walking, or dizziness, or a sudden, severe headache without 
an apparent cause.  
 
If you notice any of these symptoms, seek medical attention immediately.  
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Slide 10 Script: Warfarin should be taken once a day unless your doctor tells you 
otherwise.  However, it is important for you to know what to do if you accidentally miss 
a dose. 
 
If you forget to take your warfarin, you need to consider how long it has been since you 
were supposed to take that day’s dose. If you remember within 12 hours of when you 
were supposed to take your warfarin, take your warfarin at that time.  
 
If it has been more than 12 hours since you were supposed to take your warfarin, skip that 
dose. In either scenario, take your warfarin the next day as you normally would.  
 
 
 
Slide 11 Script: As an example, Walter usually takes his warfarin at 9:00 am but one 
morning, he forgets.  
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Slide 12 Script: At 1:00 pm, Walter realizes he did not take his warfarin that morning. It 
is safe for him to take his dose at 1:00 pm because it is only 4 hours later than his 
normally scheduled time.  
 
 
 
Slide 13 Script: However, if Walter had remembered at 10:00 pm, it would not be safe for 
him to take his warfarin that day. It has been too long, 13 hours, since that day’s dose was 
scheduled.  
 
He should take his 9:00 am dose the following day as scheduled by his health care 
professional.   
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Slide 14 Script:  Following Walter’s example and the other simple guidelines as outlined 
in this DVD, will help to ensure that you are safe while taking warfarin.  
 
It is important to remember: 
{Click 1}Not to double up on your warfarin dose, even if you have skipped a dose. This 
may lead to bruising, bleeding, or even death.  
 
{Click 2}If you miss more than one warfarin dose, contact your heath care provider.  
 
 
 
Slide 15 Script: As mentioned earlier, herbal products and dietary supplements may 
affect how warfarin works in your body. Therefore, these products should be used with 
caution and only under the direction of your health care professional when used in 
combination with warfarin.  
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Slide 16 Script: Many herbal products and dietary supplements interact with warfarin. 
These interactions can increase your risk for: bruising, bleeding,  blood clots, stroke, and 
possibly death.  
 
Your INR level will not always tell you if the herbal product or dietary supplement you 
are taking is interacting with your warfarin medication. Therefore, ask your doctor or 
pharmacist if the product or products you wish to take are safe to use while you are on 
warfarin.  
 
Let’s further discuss some of the important things you need to know about dietary 
products and herbal supplements. 
 
 
 
	  	  
97 
 
 
Slide 17 Script: Ask your doctor or pharmacist if the product you wish to take is safe to 
use while you ware on warfarin.  
 
 
 
 
Slide 18 Script:  Dietary supplements are products that contain vitamins, minerals or a 
combination of these. Supplements should not replace food but are used to complement 
the diet.  
  
For example,  a dietary supplement can contain any individual  vitamin or mineral 
including calcium, magnesium, zinc, vitamins A, C or K.  
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Slide 19 Script:  An herbal product is made from a natural source and it may contain 
vitamins, minerals, and other products including fish oils, botanicals or other naturally 
occurring compounds.  
 
Herbal products can be in capsule, liquid, or powder form. These products, such as green 
teas, ginger tablets, and garlic pills, are often used for functional support.  
 
It is important to note that garlic and ginger spices are safe to use in cooking, but do not 
confuse spices with supplements in capsule form.  
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Slide 20 Script:  Intermountain Health Care doctors and pharmacists have spent a lot of 
time researching how supplements and herbal products interact with warfarin.  
 
We will now discuss some of their findings about a few of the most popular supplements 
and herbal products on the market today.  
 
These products have been broken down into 3 categories [next slide] 
 
 
 
Slide 21 Script:  {Read three categories} 
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Slide 22 Script:  {Read list} all interfere with your warfarin.   
 
Talk to your doctor if you are currently taking, or are interested in taking these vitamins, 
minerals, or herbal products because they can increase your risk for bruising or stroke. If 
you still wish to take these products, your doctor or pharmacist can adjust your warfarin 
dose to account for their use, and he or she will monitor your INR more closely to make 
sure that they do not increase your bleeding or stroke risk.  
 
If you are taking any of these products, do not stop taking them until you talk to your 
health care professional as doing so will also alter your warfarin.  
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Slide 23 Script:  Vitamins A, D, K, E… {Read the rest of this list}are some supplements 
and herbal products that interact with warfarin. It is important to talk to your health care 
professional before starting, stopping, or continuing the use of any of these products. 
 
 
 
 
 
 
Slide 24 Script:  {Read list} may interact with warfarin. Just because we may not know if 
these supplements or herbal products interact with warfarin, it does not mean that you can 
take these without first discussing these therapies with your doctor or pharmacist.  
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Slide 25 Script:  Although we have discussed some of the most commonly used herbal 
products and dietary supplements, there are many other products that interact with 
warfarin. If a product is not on this list, that does not mean that it is safe to take. Contact 
your health care professional before using any supplement or herbal product.  
 
 
 
Slide 26 Script: Now that you know a little about which supplements and herbal products 
interact with warfarin, you need to know how to identify these products.  
 
{make supplement label pop out}: By looking at the supplement label on the back of the 
product, you can find out which vitamins, minerals, and herbal compounds are in the 
supplement.  
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Slide 27 Script: Look at this supplement facts label. There are 4 components to this label 
that you need to understand.  
 
 
 
Slide 28 Script:  First, look at the top section of the supplement facts label. This section 
shows the both the serving size and the manufacturer’s suggested use.  
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Slide 29 Script: Next, the amount per serving column, found on the left side of the label, 
lists all nutrients in the product and the quantity of each nutrient. For example, this 
supplement contains folic acid, vitamin K, vitamin A, vitamin D, Vitamin B, iron, and 
copper. 
 
 
 
Slide 30 Script:  In a smaller font at the bottom of the supplement label, all nutrients and 
other components in the product are listed. This is known as the ingredient list. 
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Slide 31 Script:  Finally, the right side of the label contains the percent daily value 
column. Here you find the recommended daily value for each nutrient contained in this 
supplement, listed as a percentage. If an asterisk(*) is present in this column, a 
recommended amount for that nutrient has not been determined.  
 
As a general rule, we recommend you find supplements which contain about 100% or 
less of the daily value for each nutrient.  Exceeding the recommended amount does not 
necessarily provide more health benefits, and it may actually be harmful. Note, this 
particular supplement contains 200% of the daily value for vitamin K. This is another 
example of why it is important to pay attention to supplement labels, and why consulting 
with your health care professional is crucial.      
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Slide 32 Script: Now that we have examined this supplement label, let’s put it to use.  
 
Look at both the amount per serving column and the ingredient list to see if there is 
anything in the product that could interact with warfarin.  
 
 
 
 
Slide 33 Script: This particular supplement contains vitamins K, A, and D. All of these 
vitamins interact with warfarin, and should be used with caution. Do not take this 
supplement until you talk to your doctor or pharmacist. 
 
This label is just one example of the type of ingredients you may find in a supplement. 
Many ingredients in supplements and herbal products interfere, interact, or may interact 
with warfarin.  
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Slide 34 Script: {Read Slide} 
 
 
 
 
 
 
 
Slide 35 Script: {Read Slide} 
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Slide 36 Script: Thank you for taking the time to view this DVD. We hope that it 
provided you with some new information that will help you better manage your warfarin 
therapy.  
 
If you have any other questions about this DVD or your supplement or herbal product 
regimen, please discuss these concerns with your health care professional.  
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APPENDIX F. ONE-ON-ONE WARFARIN AND SUPPLEMENT EDUCATION 
CURRICULUM INSTRUCTION AND EVALUATION FORM 
 
This curriculum is intended to educate patients who have atrial fibrillation about the risks 
associated with supplement and herbal product use while they are on warfarin 
anticoagulation therapy. For the purpose of this research project, a Utah State graduate 
student or undergraduate dietetics students will teach the learning module. However, this 
is also intended to be a standalone curriculum that could be taught by nurses or other 
health care professionals.  
Included for your review are: 
• The educational curriculum 
• The pre-test and post-test  
• Handouts for participants 
Please feel free to make any suggestions you may have on these components directly on 
the attached documents. After reading through the curriculum, please indicate your 
agreement with the following statements: 
4=Strongly Agree 3=Agree 2=Disagree 1=Strongly Disagree 
 
Please provide any additional comments you may have in the space below. 
  
 
 
1. The curriculum is easy to follow. 4        3       2         1 
2. The education appropriately teaches all 
outlined objectives. 
 
3. The curriculum provides all the necessary 
components to effectively teach the 
information. 
4        3       2         1 
4. Its content is accurate. 4        3       2         1 
5. The curriculum appropriately answers all pre- 
post-test questions.  
4        3       2         1 
6. The handouts are well organized and helpful.  4        3       2         1 
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APPENDIX G. DEMOGRAPHIC QUESTIONNAIRE  
 
Identification Number________ 
Age _____ 
Please circle: 
 
Gender   
   
Male    
    
Female   
  
 
Education Level 
Less than the 8th Grade 
8-12th Grade  
High School Graduate 
College Graduate 
Advanced Degree 
 
Vitamin and Mineral Supplements  
1. Do you take vitamin supplements? Yes/No 
 
2. If yes, which ones (Circle all that apply)  
   Vitamin A    Vitamin E      Vitamin D    
  Vitamin C   Vitamin K   Vitamin B  
  Calcium   Magnesium  Zinc   
  Folate   Multivitamin     Iron 
  Potassium  Selenium   Beta Carotene 
 Other (please specify): _____________________________ 
 
Herbal and Natural Medications  
1. Do you take any herbal or natural products?  Yes/No 
 
2.   If yes, which ones? (Circle all that apply) 
 Garlic   Ginger   Glucosamine 
 Ginko   Biloba   CoEnzyme Q10  
 St. John’s Wort Flaxseed  Melatonin 
 Papaya Extract Ginseng  Soy Protein Products  
Green Tea  Chondrotin   Cranberry 
Saw Palmetto  Soy   Primrose 
Red Clover  Black Cohosh  Fish oil supplements  
 Other (please specify): ___________________________ 
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If you take supplements or herbal products, please answer the following 
questions: 
 
1. Why do you take supplements or herbal products? Circle all that apply. 
a. They are good for me 
b. Recommended by family  
c. Recommended by my doctor 
d. To supplement poor eating habits 
e. Other (please specify): _________________________ 
 
2. How often do you take supplements or herbal products? 
a. Once a day 
b. Two to three times a week 
c. Once a week 
d. Every other week 
e. Once a month 
f. Other (please specify):_____________________________ 
 
3.  Do you ask your doctor before using a natural supplement or herbal 
product if it interacts with Warfarin?  Yes/No 
 
4.  If not, why? 
a. Didn’t think there was a need 
b. Forgot to mention it  
c. Other (please specify): ___________________________ 
Warfarin Intake 
1. Have you missed a warfarin dose in the past: 
a. Day 
b. 3-5 days 
c. Week 
d. Month 
e. 6 months  
f. I never miss a warfarin dose 
g. Other (please specify):____________________________ 
 
2. If you answered that you have missed a warfarin dose in the past year, 
how often does this occur? 
a. Once a week  
b. Twice  a week 
c. Once a month  
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APPENDIX H. SATISFACTION QUESTIONNAIRE  
 
 
Identification Number: _________________________ 
 
1. Which education format were you asked to complete? 
a. Take-home DVD education 
b. One-on-one education 
2. How often have you looked at the educational materials since you completed the 
initial education? 
a. Never 
b. Once 
c. Twice 
d. Other (Please specify): ______________________________________ 
Indicate your agreement with the following statements: 
4= Strongly Agree 3= Agree 2= Disagree 1= Strongly Disagree 
3. The education’s content was useful. 
4 3 2 1    
 
4. The instructional method was effective.  
4 3 2 1   
 
5. The handouts enhanced my learning 
4 3 2 1   
6. As a result of this education, I feel more comfortable with my warfarin 
prescription. 
 
4 3 2 1   
7. As a result of this education, I feel more comfortable managing my supplement 
and herbal product intake. 
4 3 2 1   
 
Additional Comments? 
 
 
 
 	  
